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ABSTRACT
Although a number of risk factors for medication-overuse headache (MOH) have been
identified within the general population, limited research exists examining clinical samples of
headache sufferers. Further, prior studies have not assessed the relative influence of risk factors
or their utility in combination.
As part of an online survey, 164 headache patients completed a demographic
questionnaire, a diagnostic interview for headache, a measure of headache-related disability,
measures of psychiatric symptoms, and measures of medication use and substance use.
Standardized mean differences were used to quantify differences between patients who met
diagnostic criteria for MOH and those who did not across five domains of predictors
(demographic characteristics, headache characteristics, psychiatric symptoms, medication use,
and substance use). The variables within each domain that best discriminated between those who
met criteria for MOH and those who did not were identified using a classification tree approach
with Bonferroni corrections. Candidate variables were then entered into a multivariate logistic
regression to predict MOH status.
Forty-three of the 164 patients (26.2%) of the sample met diagnostic criteria for MOH.
Patients with MOH were more disabled by their headaches (mean [SD]: 67.60 [6.00] vs 63.31
[6.68]) and reported more escape and avoidance behaviors in response to headache pain (14.64
[5.36] vs 10.44 [6.13]. The use of combination medication for the treatment of headache (60.5%
vs 33.1%, odds ratio 3.10, 95% confidence interval [CI] 1.51-6.36) was associated with more
than a threefold risk of MOH. These three variables were forced into a final multivariate model,
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which differentiated well between the two groups (area under the receiver operating
characteristic curve = .78; 95% CI .71-.86).
Based on these results, headache-related disability, fear and avoidance of pain-related
stimuli, and the use of combination medications for the treatment of headache best predict MOH
among treatment-seeking headache sufferers. Brief screening measures that assess relevant risk
factors may be used to aid in the identification of headache patients most likely to have MOH
and behavioral and cognitive-behavioral interventions may hold promise for the prevention of
MOH and the reduction of acute medication use among individuals with MOH.
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I. INTRODUCTION
1.1 Headache Diagnoses
Worldwide, 46% of adults suffer from an active headache disorder (Stovner, et al., 2007).
The International Classification of Headache Disorders 3rd edition-beta version (ICHD-IIIβ)
classifies headaches not attributable to identifiable organic pathology as primary headaches. The
most common primary headache disorders are migraine and tension-type headache (TTH), which
are two of the top three most prevalent medical conditions worldwide (Vos et al., 2012). In
contrast, headaches deriving from illness or injury (e.g., trauma, surgery, infection, illicit
substance use, and medication overuse; ICHD-IIIβ) are classified as secondary headaches.
Primary headaches comprise the large majority of headaches experienced by the population.
With the exception of the very rare condition of cluster headache, primary headache disorders
are more prevalent in women than in men across cultures (Stovner et al., 2007), making
headache a significant women’s health concern.
A recently published meta-analysis indicates that, migraine affects 11.6% of adults
worldwide (Woldeamanuel & Cowan, 2017). Migraine attacks typically last between 4 to 72
hours and are characterized by unilateral pulsating head pain of moderate to severe intensity.
Migraine may be aggravated by routine physical activity and for diagnosis must produce nausea,
vomiting, or both photophobia (sensitivity to light) and phonophobia (sensitivity to sound). In a
significant minority of cases, migraine attacks are preceded by aura, a constellation of temporary
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focal neurological symptoms that are commonly visual in nature (e.g., seeing spots or zigzag
lines, blurry vision). Aura symptoms usually develop gradually over 5-20 minutes and last for
less than an hour, after which time the head pain begins (ICHD-IIIβ; Lipton, Scher,
Silberstein, Liberman, & Bigal, 2008).
Tension-type headache is the most common type of primary headache, affecting
approximately 42% of adults worldwide (Stovner et al., 2007). Tension-type headaches may last
anywhere from 30 minutes to 7 days. Unlike migraine, the pain of TTH is characterized as
bilateral, pressing or tightening in quality, of mild to moderate severity, and not worsened by
routine activity (Rasmussen, Jensen, Schroll, & Olesen, 1991). Nausea and vomiting are not
typically associated with TTH, but photophobia or phonophobia (not both) may accompany these
headaches, although they are typically of lesser severity compared to that observed in migraine
(ICHD-IIIβ; Jensen, 2003).
Cluster headache is a very rare but severe type of primary headache. Approximately 1 in
1000 people suffer from cluster headache (Fischera, Marziniak, Gralow, & Evers 2008). Left
untreated, cluster headaches typically last for 15 to 180 minutes. Cluster headache is
characterized by unilateral, excruciating pain typically of orbital or supraorbital temporal
distribution (ICHD-IIIβ). Attacks are accompanied by ipsilateral autonomic symptoms (e.g.,
lacrimation, swelling of the orbital socket) and produce restlessness and agitation that often
manifest as continuous pacing because of the extreme pain severity (Torelli & Manzoni, 2003).
Individuals who suffer from cluster headache often report a significant personal and
socioeconomic burden as a result (Jensen et al., 2007).
2

Migraine and other forms of recurrent headache are among the most common and
disabling disorders of the nervous system (Andlin-Sobocki, Jonsson, Wittchen, & Olesen, 2005;
Olesen, Gustavsson, Svensson, Wittchen, & Jonsson, 2012; Rasmussen, Jensen, & Olesen,
1992). Due to the financial costs (Hu, Markson, Lipton, Stewart, & Berger, 1999) conferred to
both the individual and to society, headache is among the top ten most disabling conditions
worldwide (Stovner et al., 2007; Vos et al., 2012) and among the top five most disabling
conditions for women (Stovner, et al., 2007). According to the National Ambulatory Care Survey
(NAMCS), “pain in the head” was among the top 20 reasons for outpatient doctor’s visits in
2009 (National Center for Health Statistics [NCHS], 2010), and 7.7 million emergency
department (ED) visits were attributed to acute headache in 2010 (Mazer-Amirshahi, et al.,
2014). Accordingly, head pain is among the top five leading causes of ED visits, accounting for
3.1% of ED visits between 2009 and 2010 (Burch, Loder, Loder, & Smitherman, 2015;
Smitherman, Burch, Sheikh, & Loder, 2013).
Most frequently, primary headache disorders occur episodically (< 15 days per month);
however, approximately 3-5% of adults in the general population experience “chronic” headache
(CH; Castillo, Munoz, Guitera, & Pascual, 1999; Lanteri-Minet et al., 2003; Lu, Fuh, Chen,
Juang, & Wang, 2001; Stovner, et al., 2007; Wang, et al., 2000; Westergaard, Glumer, Hansen,
& Jensen, 2014). Chronic headache disorders are those with a frequency of 15 or more headache
days per month (ICHD-IIIβ). Even though episodic headache (EH) is much more common,
individuals with CH make up a large percentage of patients seen in U.S. headache clinics
(Mathew, 1993). Compared to individuals with EH, individuals with CH experience lower
quality of life, increased disability, reduced work productivity, more frequent and severe
psychiatric comorbidities, more and longer hospitalizations, and increased medical costs (Buse,
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Silberstein, Manack, Papapetropoulos, & Lipton, 2012; Lanteri-Minet, Duru, Mudge, & Cottrell,
2011).
1.2 Acute Medications as Treatment for Headache
Headache patients commonly use acute medications in order to relieve the pain and
disability associated with attacks. As such, headache is among the most common reasons for
acute pain medication consumption in the general population (Eggen, 1993; Meskunas, Tepper,
Rapoport, Sheftell, & Bigal, 2006; Zwart, Dyb, Hagen, Svebak, & Holmen, 2003). Acute
medications prescribed for headache include headache-specific agents (e.g., ergotamine
derivatives and triptans), dopamine antagonists (e.g. metochloproamine and prochlorperazine),
nonspecific medications (e.g. nonsteroidal anti-inflammatory drugs [NSAIDS]), opioids (e.g.,
codeine and hydrocodone), barbiturates (e.g., butalbital), and combination analgesics (e.g.
aspirin, acetaminophen, and caffeine combinations; Silberstein, Freitag, & Bigal, 2008).
Ergotamine was the first acute medication developed specifically for the treatment of
headache. Ergotamine was the treatment-of-choice for migraine until the late 1980s and early
1990s when triptans were introduced and quickly supplanted ergotamine due to superior efficacy
and more favorable side effect profiles. Current consensus guidelines recommend triptans as
first-line options for the treatment of headache (Marmura, Silberstein, & Schwedt, 2015;
Silberstein et al., 2000). As a result, triptans accounted for 80% of the over 6 million
prescriptions written for acute migraine medications in outpatient clinics in 2009 (NCHS, 2010).
Although triptans are frequently prescribed by headache specialists, prescription practices vary
considerably by setting. According to recent analyses of ED prescription practices, triptans are
prescribed in few (<2%) ED visits for headache. Instead, opioids (22.8% – 30.5%) and NSAIDS
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(16.9% - 31.4%) were far more likely to be prescribed in the ED (Mazer-Amirshahi et al., 2014;
McCarthy & Cowan, 2015). Despite consensus guidelines that recommend opioid analgesics and
butalbital not be used as first-line agents (Loder, Weizenbaum, Frishberg, & Silberstein, 2013;
Silberstein et al., 2000), opioids were more frequently prescribed to treat headache during ED
visits in 2010 (35.0%) than in 2001 (20.6%; Mazer-Amirshahi et al., 2014).
Although acute headache medications are vital to the management and treatment of
headache, their overuse is frequently associated with CH and may lead to a gradual
transformation from EH to CH termed “chronification” (Lipton, 2009; Mathew, 1998).
Approximately 30% of individuals with CH (Scher, Midgette, & Lipton, 2008) and more than
70% of individuals treated for CH in headache clinics (Bigal, Rapoport, Sheftell, Tepper, &
Lipton, 2004) overuse acute headache medications. On average, individuals with CH use acute
headache medications on 18.3 days per month, and 23% report taking acute medications on a
daily basis (Scher, Lipton, Stewart, & Bigal, 2010).
1.3 Classification of Medication-Overuse Headache
Frequent use of acute headache medications may produce a form of secondary headache
referred to as medication-overuse headache (MOH), which was first described in the 1950s and
1960s when chronic intractable headache was observed among frequent users of ergotamine
(Peters & Horton, 1951; Horton & Peters, 1963). Medication-overuse headache currently is
defined as CH (headache frequency > than 15 days a month) coinciding with regular overuse of
acute headache medications. “Overuse” is quantified as use on 10 or more days per month for
triptans, ergotamine, and combination analgesics or 15 or more days per month for simple
analgesics and combinations of acute medications, for more than 3 months. Headache typically,
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but not always, remits after overuse stops (ICHD-IIIβ), which may require inpatient
hospitalization for supervised medication withdrawal. Table 1 displays the ICHD-IIIβ criteria for
MOH.
Table 1. The International Classification of Headache Disorders (ICHD-3β) Criteria for
Medication-Overuse Headache
A. Headache occurring on ≥15 days per month in a patient with a pre-existing
headache disorder.
B. Regular overuse for >3 months of one or more drugs that can be taken for acute,
and/or symptomatic treatment of headache.
1. Regular intake of ergotamine, triptans, opioids, or combination analgesics on
≥10 days per month for >3 months.
2. Regular intake of simple analgesics on ≥15 days per month for >3 months.
3. Regular intake of any combination of ergotamine, triptans, simple analgesics,
NSAIDS, and/or opioids on a total of ≥ 10 days per month for >3 months
without overuse of any single drug or drug class alone.
C. Not better accounted for by any other ICHD-3 diagnosis.
Note. International Headache Society. (2013). The International Classification of Headache
Disorders, 3rd ed. (beta version). Cephalalgia, 33, 629-808.
1.4 Medication-Overuse Headache: Prevalence and Epidemiology
The prevalence of MOH is 1-2% within the general population (Colas, Munoz,
Temprano, Gomez, & Pascual, 2004; Diener & Limmroth, 2004; Stovner et al., 2007;
Westergaard et al., 2014). Despite its relatively low prevalence in population studies, MOH is
disproportionately common in pain clinics and specialty headache centers. Schmid and
colleagues (2013) reported that 29% of adult pain patients referred to an interdisciplinary pain
clinic met diagnostic criteria for MOH. Furthermore, up to 25% of adult headache patients in
Europe (Zeeberg, Olesen, & Jensen, 2006) and 50% of adult patients in the United States
(Meskunas et al., 2006) present with MOH. Estimates of the mean duration of primary headache
among those with MOH are 14.9 – 20.4 years, and the mean duration of medication overuse is
4.0 – 10.3 years (Deiner & Dahlof, 1999; Dong et al., 2015). Overall, MOH is more common in
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women than in men (Bigal et al., 2004; Jonsson, Hedenrud, & Linde, 2011; Straube et al., 2010),
and mirrors the gender difference in migraine prevalence. It is unclear whether women are
actually more likely than men to misuse their medication, or whether gender difference in MOH
are a function of disproportionate headache prevalence (Burch et al., 2015; Westergaard et al.,
2014). Medication-overuse headache is most prevalent among middle-aged individuals of both
genders (D’Amico, Grazzi, Usai, Rigamonti, Curone, & Bussone, 2005; Jensen & Bendtsen,
2008; Westergaard et al., 2014) with mean age of onset at 45 years (Colas et al., 2004). Because
MOH onset often occurs during years of peak productivity, MOH imparts a significant burden on
patients and society.
1.5 Disability Associated with Medication-Overuse Headache
Medication overuse headache was recently identified as the 18th leading cause of
disability worldwide (Vos et al., 2015). Both the individual and society are negatively impacted
by MOH due to lost productivity, elevated disability, increased medical costs, and a high burden
on health care services (D’Amico et al., 2005; Linde et al., 2012). Moreover, MOH is
substantially more disabling than other forms of headache. Individuals with MOH experience
considerable work-related impairment, as the number of workdays lost by MOH patients is
nearly six times higher than the number of workdays lost by those with episodic migraine (EM;
Raggi et al., 2015). The annual personal cost of MOH is 3 times higher than the personal cost of
migraine and more than 10 times higher than that of TTH (Linde et al., 2012). Some evidence
suggests that MOH may result in even greater reductions in quality of life than other forms of
CH (Lanteri-Minet et al., 2011). For these reasons, some have asserted that MOH is prevalent
and among the most costly neurological condition known (Russell & Lundqvist, 2012).
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1.6 Treatment of Medication-Overuse Headache
The withdrawal of overused medications, either abruptly or via gradual tapering, is the
treatment-of-choice for MOH (Evers & Jensen, 2011; Obermann, Bartsch, & Katsarava, 2006).
Headache frequency gradually declines over the days and weeks following withdrawal of the
overused medication (Katsarava, Fritsche, Diener, & Limmroth, 2001; Relja, Granato, Bratina,
Antonello, & Zorzon, 2006). The withdrawal of opioids, barbiturates, and benzodiazepines are
often associated with significant withdrawal symptoms (e.g., worsening of headache, nausea,
vomiting, restlessness, anxiety, and nervousness); therefore, gradual withdrawal may be the best
option for patients overusing these agents. Abrupt withdrawal is the treatment-of-choice for
patients who misuse triptans, ergots, combination analgesics, simple analgesics, and NSAIDs, as
severe withdrawal symptoms are uncommon with these medications (Evers & Jensen, 2011).
Withdrawal symptoms typically last for 2-14 days, and the duration of withdrawal symptoms is
typically shorter for patients who overused triptans in comparison to those who overused
ergotamine or NSAIDs (Katsarava et al., 2001; Rabe et al., 2013). Initiation of a prophylactic
regimen in conjunction with withdrawal of the acute medication is often associated with better
outcomes in comparison to acute medication withdrawal alone (Chiang, Schwedt, Wang, &
Dodick, 2016). For example, initiation of a prophylactic regimen in conjunction with withdrawal
of the acute medication is associated with significant reductions in headache frequency and
improvements in quality of life, headache-related disability, anxiety, and depression (Bendtsen et
al., 2014; Wallasch & Kropp, 2012; Zebenholzer, Thamer, & Wober, 2012).
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1.7 Pathophysiology of Medication-Overuse Headache
The pathophysiology of MOH remains unclear. Given that MOH can be caused by the
excessive use of any class of migraine-specific or non-specific acute medication, it is unlikely
that MOH is attributable to the action of any specific agent. Rather, it seems more likely that
acute pain medications used to treat headache share a common mechanism that is capable of
producing headache chronification (Srikiatkhachorn, le Grand, Supornsilpchai, & Storer, 2014).
In line with this hypothesis, neuronal hyperexcitability in the cerebral cortex and trigeminal
system following the excessive use of acute pain medications, has been identified as a
pathophysiological mechanism that may underlie central sensitization and cortical spreading
depression (CSD; an analog for migraine aura).
Prolonged exposure to opioids may produce allodynia and hyperalgesia for long periods
after the discontinuation of the medication (Ali, 1986; Arner & Meyerson, 1988; De Felice &
Porreca, 2009; Johnson, Hutchinson, Williams, & Rolan, 2013). Calcitonin gene-related peptide
(CGRP) plays a prominent role in initiating vasodilation of the intracranial blood vessels and is
implicated in the pathogenesis of migraine (De Felice & Porreca, 2009) and increased expression
of CGRP has been observed in the dorsal root ganglia following chronic administration of
opioids (Belanger, Ma, Chabot, & Quirion, 2002; Ma, Zheng, Kar, & Quirion, 2000). Therefore,
changes in the expression of CGRP may play a key role in the pronociceptive neural adaptations
associated with MOH. In addition to changes in the expression of CGRP, sustained exposure to
opioids is also associated with enhanced glutamate release (Gardell et al., 2002), expansion of
cutaneous receptive fields, lower thresholds of dura-sensitive medullary dorsal horn neurons
(Okada-Ogawa, Porreca, & Meng, 2009), and activation of toll-like receptor-4 on glial cells (De
Felice & Porreca, 2009; Johnson et al., 2013). Although hyperalgesia is more commonly
8

associated with opioid medications, prolonged exposure to triptans can also produce changes in
trigeminal pain nociceptive systems. Enduring but reversible cutaneous tactile allodynia has been
observed in rats following chronic triptan administration. This change is associated with
increased levels of CGRP in afferent trigeminal ganglionic (TG) neurons (De Felice et al.,
2010b) and increased expression of nitric oxide synthase in the trigeminal neurons that innervate
the dura of rats (DeFelice et al., 2010a). Considered together, this evidence suggests that the
overuse of opioids and triptans can produce a persistent proinflammatory state and long-lasting
pronociceptive adaptation in trigeminal primary afferent neurons located in the peripheral
nervous system.
In addition to sensitization of neurons in the trigeminal system, serotonergic dysfunction
has been implicated in the development of MOH as well as the affective disorders that are
frequently comorbid with headache and (Atasoy, Atasoy, Unal, Emre, & Sumer, 2005; Hagen,
Linde, Steiner, Stovner, & Zwart, 2012). Triptans are presumably effective due to their action as
agonists on the serotoninergic system. Triptans act on 5-HT1B/1D receptors which primarily exert
an inhibitory effect. The acute and systematic administration of triptans decreases 5-HT
synthesis in brain areas such as the dorsal raphe nucleus. However, chronic administration of
triptans produces the paradoxical effect of increasing 5-HT synthesis. Potential mechanisms for
this increase in 5-HT synthesis include a down-regulation or desensitization of 5-HT1 receptors
and/or an unmasking of excitatory triptan-sensitive 5-HT receptors (Dobson, Tohyama, Diksic,
& Hamel, 2004). Like triptans, acetaminophen acts on the serotoninergic system. However,
acetaminophen acts on 5-HT2A receptors. Unlike to 5-HT1 receptors, activation of 5-HT2A
receptors is associated with increased neuronal excitability. The acute administration of
acetaminophen is associated with significant increases of 5-HT and a decrease in the number of
9

5-HT2 receptors available in the cerebral cortex (Pini, Sandrini, & Vitale, 1996). However,
chronic administration of acetaminophen to rats has been found to increase the frequency of CSD
and CSD-evoked increases of 5-HT2A serotonin receptor expression in the cerebral cortex and
trigeminal nucleus caudalis (Supornsilpchai, le Grand, & Srikiatkhachorn, 2010a &
Supornsilpchai, le Grand, & Srikiatkhachorn, 2010b).
Impairment of the endogenous 5-HT dependent pain modulation system may underlie the
cortical sensitization and pain facilitation associated with MOH. Animal models suggest that
decreased availability of 5-HT is associated with upregulations in the expression of
pronoiceptive 5-HT2A receptors in the cortex and trigeminal system, increased CGRP expression
in the TG, and increase susceptibility to CSD (Le Grand, Saengjaroentham, Supronsilpchai, &
Srikiatkhachorn, 2010; Maneepak, le Grand, & Srikiatkhachorn, 2009; Saengjaroentham,
Supornsilpchai, Srikiatkhachorn, le Grand, 2012; Supornsilpchai, le Grand, & Srikiatkhachorn,
2010a; Supornsilpchai, Sanguanrangsirikul, Maneesri, & Srikiatkhachorn, 2006). These findings
suggest that the chronic administration of acetaminophen or triptans may negatively impact
central pain modulation systems by either decreasing nociceptive inhibition or by increasing
nociceptive facilitation.
In summary, more research is needed in order to better understand the pathophysiology of
MOH; however, chronic exposure to acute headache medications such as opioids,
acetaminophen, and triptans is associated with increased neuronal excitability in the trigeminal
system and cerebral cortex. Increased neuronal excitability in the cortex may increase
susceptibility to CSD; whereas, increased excitability of trigeminal neurons may facilitate
peripheral and central sensitization. Such neuronal excitability following the overuse of acute
headache medications is thought to be secondary to impairment of serotoninergic pain
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modulation systems that exert a strong influence on the trigeminal system. The depletion of 5HT following the excessive use of acute headache medication may be driven at least in part by
upregulation of pronociceptive 5-HT2A receptors that increase susceptibility to CSD.
Furthermore, low 5-HT levels may also increase the release of CGRP and the subsequent
sensitization of trigeminal nociceptors. Therefore, impairment of the serotonin-dependent pain
modulation systems subsequent to chronic headache medication may be central to increased pain
sensitivity and MOH.
1.8 Medication Use Patterns Associated with Medication-Overuse Headache
All acute medications used for the treatment of headache are capable of causing MOH
(ICHD-IIIβ; Obermann et al., 2006), but as prescription practices have changed so have the rates
of MOH caused by various medications. Meskunas and colleagues (2006) randomly reviewed
the charts of patients seen at a single headache center during the years of 1990, 1995, 2000, and
2005. Between 1990 and 2005 MOH attributed to ergotamine and combination analgesics
declined significantly (18.6% to 0% for ergotamine and 42.2% to 13.6% for combination
analgesics). Simultaneously, frequency increased significantly for MOH attributed to the overuse
of triptans (0% to 21.6%), simple analgesics (8.8% to 31.8%), and for combinations of acute
medications (9.8% to 22.7%). Although there was a decrease in MOH associated with opioid
overuse during this same period (18.6% to 9.1%), the trend was not statistically significant.
Individuals with CH are more likely to use opioid-combination analgesics in comparison
to those with EH or no headache (Bigal & Lipton, 2008; Scher et al., 2010). The use of opioids
for the treatment of headache is controversial. Evidence suggests that opioids are likely to
sensitize the central nervous system to pain and increase the risk of MOH (Bigal & Lipton, 2008;
11

Johnson et al., 2013). Compared to individuals using acetaminophen to treat their migraines,
individuals using opioids are at an increased risk for migraine chronification (Bigal, Serrano,
Buse, Scher, Stewart, & Lipton, 2008; Scher et al., 2010). The management of headache via
opiates is not recommended as a first-line treatment option due to relatively lower efficacy in
comparison to a number of other acute medications as well as a number of adverse effects
including tolerance, dependence, and addiction (Levin, 2014). Further, the critical dose of
exposure likely to produce a transition from episodic to chronic headache is low (approximately
8 days per month; Bigal & Lipton, 2008). Despite these adverse effects, opioids are frequently
prescribed in clinical practice, particularly in ED settings (Mazer-Amirshahi et al., 2014;
McCarthy & Cowan, 2015).
Despite the efficacy and cost-effectiveness of triptans (Asseburg, Peura, Oksanen,
Turunen, Purmonen, & Martikainen, 2012; Thorlund et al., 2014), a large proportion (43%) of
individuals with chronic migraine (CM) overuse them (Ferrari et al., 2007). As a result, triptans
are frequently implicated in the development of MOH. Medication-overuse headache may
develop more quickly and at a lower dosage for individuals who are prescribed triptans in
comparison to individuals who are prescribed other acute headache medications. The mean
critical duration of overuse (calculated by subtracting the duration of MOH from the duration of
medication overuse) is shorter for triptans (1.7 years) than for ergots (2.7 years) and simple
analgesics (4.8 years). Among patients with MOH, the mean monthly number of doses necessary
to produce MOH is lower for triptans (18 doses per month) compared to ergots (37) and simple
analgesics (114; Limmroth, Katsarava, Fritsche, Przywara, & Diener, 2002).
Simple analgesics, NSAIDs, and combination analgesics are frequently used to treat
headache because they are affordable and readily available over-the-counter (Dong et al., 2015;
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Zwart, Dyb, Hagen, Svebak, Stovner, & Holmen, 2004), particularly outside of the United States
where triptans are less likely to be prescribed. For instance, two-thirds of a Spanish sample with
MOH reported the use of simple analgesics alone or in combination with ergotamine (Colas et
al., 2004), whereas combination analgesics were most commonly overused by Chinese patients
with MOH (Dong et al., 2015). In the United States, individuals with tension-type headache TTH
frequently use over-the-counter medications such as NSAIDS (Lyngberg, Rasmussen, Jorgensen,
& Jensen, 2005). NSAIDs have been found to exert a dose-dependent protective effect such that
NSAIDs are associated with a decreased risk for MOH among individuals with low to
intermediate headache frequency (Bigal & Lipton, 2009; Bigal, et al., 2008; Scher at al., 2010),
but increased risk for chronification and MOH among individuals who have 10 or more
headaches per month (Bigal & Lipton, 2009). Consequently, patients with chronic tension-type
headache (CTTH) are at an increased risk for MOH.
Analgesics are used and overused in attempts to treat a wide variety of chronic pain
conditions; therefore, the question has been raised whether the frequent use of analgesics can
induce CH in previously headache-free individuals. Medication-overuse headache is most
frequently diagnosed in patients with a prior history of migraine (Radat et al., 2008; Zwart et al.,
2003) and to a lesser degree TTH (Silberstein, Lipton, & Sliwinski, 1996). Contradictory to longheld clinical lore, patients with cluster headache may also develop MOH; however, cluster
headache patients with a personal or family history of migraine appear to be at a much greater
risk for MOH than individuals with no personal or family history of migraine (Paemeleire, Evers,
& Goadsby, 2008). Although individuals with a history of primary headache may experience
chronification following the overuse of analgesics prescribed for conditions other than headache,
MOH is very rare among individuals without a history of primary headache. For example,
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patients with no prior history of primary headache who consumed large amounts of pain
medications for the treatment of arthritis and irritable bowel syndrome did not show an increased
incidence of CH (Bahra, Menon, & Goadsby, 2003; Lance, Parkes, & Wilkinson, 1988;
Wilkinson, Becker, & Heine, 2001). Schmid and colleagues (2013) found that interdisciplinary
pain patients with a history of primary headache had 13.1 times greater odds of having MOH
than patients without a history of primary headache. However, individuals with primary
headache who are diagnosed with comorbid chronic musculoskeletal pain or gastrointestinal
complaints appear to be at greater risk for MOH compared to individuals without comorbid pain
or gastrointestinal complaints (Hagen et al., 2012). This increased risk may be in part attributable
to greater access to pain medications, but it appears unlikely that individuals with no prior
history of headache will develop headache “de novo” as a result of medication overuse for
another condition.
1.9 Modifiable Risk Factors for Medication-Overuse Headache
In addition to medication-taking behaviors, a variety of other factors are associated with
increased risk for MOH. Although some risk factors such as gender and headache diagnosis are
not modifiable, others are modifiable and should be emphasized because they are amenable to
intervention. Modifiable risk factors include low socioeconomic status (SES), high body mass
index (BMI), substance use and abuse, and mood and anxiety disorders.
Socioeconomic status is strongly associated with MOH. Compared to individuals without
headache and patients with other headache diagnoses, patients with MOH are more likely to
report a secondary school education or lower, be unemployed, and have a lower household
income (Dong et al., 2015; Jonsson et al., 2011). Despite a clear connection between MOH and
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SES, the direction of the relationship is unclear, and longitudinal research is needed to determine
whether those with low socioeconomic status are more likely to develop MOH or whether MOH
instead limits their professional and economic advancement.
Maladaptive health behaviors and lifestyle factors are frequently associated with
headache chronification (Bigal et al., 2008; Scher et al., 2008; Westergaard, Glumer, Hansen, &
Jensen, 2016). Among individuals with MOH, 21.9% are obese (Body Mass Index [BMI] ≥30),
and individuals with MOH are more likely to be obese than headache-free controls, those with
EM, and individuals with chronic headache without medication overuse (Straube et al., 2010;
Westergaard, Glumer, Hansen, & Jensen, 2016). Thus, modifiable health behaviors such as diet
and physical activity may play a role in the development of obesity and MOH. Hagen and
colleagues (2012) provided support for this hypothesis when they found that physical inactivity
more than doubled (OR = 2.7) the risk for MOH. Although some people with MOH may adopt a
sedentary lifestyle in an attempt to avoid headache pain, prospective data suggest that obesity
most often precedes increased headache frequency (Bigal, Liberman, & Lipton, 2006).
In addition to SES and health behaviors, substance-use has also been explored in relation
to MOH. Limited evidence suggests that MOH patients are more likely than migraineurs to
report a personal history of substance abuse or dependence (OR = 7.6) and a family history of
alcohol or drug use disorders (OR = 2.8). Although dependence is seen among who overuse
triptans, dependence was most common among individuals who overused opioids (Radat et al.,
2005). Specific substances linked to an increased risk for MOH include prescription medications
and tobacco. Medication-overuse headache patients were also more likely than headache-free
controls and individuals with EM to be active smokers (Straube et al., 2010). Further, a
longitudinal population-based study found that individuals who used anxiolytics such as
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benzodiazepines were at a five times greater odds (OR = 5.2) and smokers were at a more than
doubled odds for developing MOH, in comparison to individuals who did not use these
substances (Hagen et al., 2012). By comparison, alcohol use and illicit drug use do not appear to
be associated with an increased risk for the development of MOH (Hagen et al., 2012;
Westergaard et al., 2016), likely because these substances trigger headache for many individuals.
Notably, alcohol consumption is frequently lower among headache patients in comparison to
headache-free controls (Straube et al., 2010).
Comorbid psychiatric disorders are reported by a large majority (84%) of patients with
MOH (Wallasch & Kropp, 2012). Compared to migraineurs who did not misuse acute headache
medications, MOH patients are more likely to suffer from major depressive disorder (OR =
21.8), generalized anxiety disorder (OR = 6.0), panic disorder with or without agoraphobia (OR
= 12.1), and social phobia (OR = 4.3; Radat et al., 2005). Thus, symptoms of anxiety and
depression may act as risk factors for headache chronification and may predict inadequate
response to acute headache medications. Indeed, a longitudinal population-based study found
that individuals with elevated symptoms of anxiety and depression were at nearly five times
greater odds (OR = 4.7) of developing MOH than individuals who were not anxious or depressed
(Hagen et al., 2012). Findings from treatment studies indicate that symptoms of anxiety and
depression are reduced in MOH patients who undergo inpatient treatment that includes
detoxification and initiation of a preventive headache medication (Zebenholzer et al., 2012).
Similar results have been found with outpatient treatment studies, as the number of patients with
depression anxiety decreased by 50.7% and 27.1%, respectively (Bendtsen et al., 2014). Taken
together, these findings suggest that symptoms of anxiety and depression are closely tied to
medication overuse and may influence pain coping abilities. Both psychiatric symptoms and
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chronic pain can increase an individual’s perception of and focus on pain. As a result, individuals
with headache may become fearful of headache pain and increase their analgesic consumption in
an attempt to avoid the experience of pain.
Despite strong evidence that anxiety and depression are associated with MOH, there is a
paucity of research examining the role of psychological variables specifically pertaining to the
experience of pain, particularly cognitive appraisals of pain such as fear and anxiety. According
to the fear-avoidance model of chronic pain (Vlaeyen & Linton, 2000), when pain is interpreted
as non-threatening, individuals continue engagement in daily activities and functional recovery is
facilitated. However, when pain is interpreted as threatening, individuals may begin to fear pain
and engage in escape and avoidance behaviors. In the case of CH, it is not usually possible to
avoid pain entirely; however, headache patients are often instructed to take headache medication
as early as possible in the headache episode. In the short-term, hypervigilance and the avoidance
of pain are adaptive, and the patient is reinforced both negatively (i.e., the headache is prevented)
and positively (i.e., the patient is able to engage in daily activities) for taking headache
medication at the first sign of headache. However, prolonged hypervigilance may prompt
avoidance of physiological sensations and contexts actually unrelated to the experience of
headache. As a result, repeated avoidance of headache-related stimuli may have the paradoxical
long-term effect of increasing pain sensitivity, health care utilization, suffering, and disability
(Asmundson, Norton, & Veloso, 1999; Black, Fulwiler, & Smitherman, 2015; McCracken &
Dhingra, 2002; Norton & Asmundson, 2004; Vlaeyen, Snijders, Boeren, & van Eek, 1995).
Headache sufferers frequently endorse high levels of pain-related anxiety and fear (Black et al.,
2015). As a result, these individuals may begin to engage in a maladaptive pattern of avoidance
that manifests as overuse of acute headache medications (Asmundson, Wright, Norton, &
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Veloso, 2001) and increased headache frequency (Black et al., 2015). Furthermore, a recent
study of migraineurs found that FOP accounted for more variance in disability than gender,
anxiety, and depression combined (Black et al., 2015). In light of these findings, FOP may act as
a risk factor for MOH, but it remains under-researched in comparison to other variables.
1.10 Aims of the Present Study
The goal of the present study is to identify demographic, headache, psychiatric,
medication use, and substance use variables jointly associated with MOH in a population of
adults seeking treatment for primary headache disorders. A large body of research examining the
prevalence and predictors of MOH makes clear that gender, headache diagnosis, SES, BMI,
substance use, anxiety, and depression are independent risk factors for MOH (Dong et al., 2015;
Hagen et al., 2012; Jonsson et al., 2011; Schmid et al., 2013; Straube et al., 2010). However,
existing research has not empirically examined the comparative importance of these risk factors,
and the overwhelming majority of research on MOH-related variables has been conducted
among population samples drawn from outside of the United States. While these endeavors have
increased our understanding of MOH, a strong need remains to investigate associated factors
comparatively and among clinical samples given their disproportionate use of healthcare services
and prevalence among headache specialty clinics (25-50% of patients; Meskunas et al., 2006;
Zeeberg et al., 2006). Thus, the present study utilized treatment-seeking headache patients and a
statistical approach that permits comparative and combinatorial analyses of variables that best
predict MOH status. The current study serves not only to identify variables most strongly
associated with MOH among treatment-seeking headache patients in the United States, but to
inform the development and refinement of MOH assessment tools. Finally, the current study aids
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future MOH prevention and intervention efforts by focusing on modifiable risk factors that are
amenable to change.
1.11 Goals & Hypotheses
The following goals and hypotheses were proposed:
Study Goal 1: Determine the demographic, headache-related, psychiatric, medication-use, and
substance abuse variables that best differentiated individuals with MOH from treatment-seeking
headache sufferers who did not meet criteria for MOH.
Hypothesis 1a: Compared to other demographic variables, gender would be most strongly
associated with MOH, as women would be more likely to endorse MOH than men.
Hypothesis 1b: Compared to other headache-related variables, headache characteristics
commonly associated with migraine would be most strongly associated with MOH, as
patients who reported headache duration of 4 hours or longer, patients who endorsed
nausea during headache episodes, and patients who were sensitive to light and sound
during headache episodes would be more likely to endorse MOH than patients who did
not report these symptoms.
Hypothesis 1c: Compared to other headache medications, the use of opioids would be
most strongly associated with MOH, as individuals who used opioids for the treatment of
headache pain would be more likely to endorse MOH relative to patients who used other
medications for the treatment of headache.
Hypothesis 1d: Compared to other psychiatric variables, FOP would be most strongly
associated with MOH, as patients who endorsed high FOP would be more likely to meet
diagnostic criteria for MOH than patients with low FOP.
19

Hypothesis 1e: Compared to other substance abuse variables, the use or misuse of
opioids, anxiolytics, and sedatives would be most strongly associated with MOH, as
patients who used or misused opioids, anxiolytics, and sedatives would be more likely to
meet diagnostic criteria for MOH than patients who did not overuse opioids, anxiolytics,
and sedatives.
Study Goal 2: Identify the combination of predictor variables that best differentiated MOH
patients from treatment-seeking headache sufferers who did not meet criteria for MOH.
Hypothesis 2a: Gender, headache characteristics associated with migraine (headache
duration ≥ 4 hours, nausea, photophobia, and phonophobia), the use of opioids for
headache pain, FOP, and the use or misuse of opioids, anxiolytics, and sedatives would
each be uniquely associated with MOH status.
Hypothesis 2b: In conjunction, gender, headache characteristics associated with migraine
(headache duration ≥ 4 hours, nausea, photophobia, and phonophobia), the use of opioids
for headache pain, FOP, and the use or misuse of opioids, anxiolytics, and sedatives
would best differentiate MOH patients from treatment-seeking headache sufferers who
did not meet criteria for MOH.
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2. METHODS
2.1 Participants
Participants were patients treated for headache at Oxford Neurology Clinic within the last
six years. Oxford Neurology Clinic is located in Oxford, Mississippi and provides care to
patients with a variety of diseases of the nervous system, including headache. The clinic offers
an array of services including consultation and management of primary headache disorders, and
our lab has an existing collaborative research relationship with the owner and chief neurologist,
Dr. Malcolm Roland, who is board-certified in both neurology and sleep medicine. Participants
were at least 18 years of age and had a previously documented diagnosis of migraine, TTH, or
cluster headache. Assuming a medium to large effect size (OR = 3.14), a power level of 0.80,
and an alpha level of 0.05, a total sample size of 162 was required (Faul, Erdfelder, Buchner, &
Lang, 2009).
2.2 Materials
2.2.1 Demographic Questionnaire
The Demographic Questionnaire was composed of a number of questions assessing basic
information such as age, gender, education, socioeconomic status, height, and weight. This
measure can be found in Appendix A.
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2.2.2 Structured Diagnostic Interview for Headache – 3
The Structured Diagnostic Interview for Headache – 3 (SDIH-3; Andrew, Penzien, Rains,
Knowlton, & McAnulty, 1992; Smitherman, Penzien, Rains, Nicholson, & Houle, 2014) is a
computer-administered instrument designed to determine the presence of primary headache
disorders based on the diagnostic criteria set out by the ICHD-IIIβ (2013). The included 21 items
afforded differential diagnosis of primary headache disorders, while also providing qualitative
data about headache type, frequency, pain intensity, and duration. Further, the instrument
provided information about the experience of aura and cluster headaches, and was used to assess
secondary causes such as head injury or trauma and medication overuse. For the purpose of this
study, questions related to headache disability and headache triggers were omitted as disability
was addressed in a subsequent measure and headache triggers were not relevant to the objectives
of the present study. This measure can be found in Appendix B.
2.2.3 Headache Medication Use Questionnaire
Headache medication use (e.g. NSAIDS, triptans, and antiepileptics) and days per month
using each headache medication were of particular interest. Medication use data was obtained
using items included as part of the American Migraine Prevalence and Prevention (AMPP) study
(Lipton, Serrano, Nicholson, Buse, Runken, & Reed, 2013). Respondents were asked to endorse
which headache medications they used, the number of days per month of use, and the duration
each medication had been used at the current frequency. Given that several preventive
medications commonly prescribed for the treatment of headache were originally developed for
the treatment of other conditions (e.g. antidepressants and antiepileptics), participants were asked
to specify whether they were taking each medication for the treatment of headache. Acute and
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preventive medications commonly used for headache were listed in the questionnaire by both
brand and generic names. Acute medications classes included commonly used NSAIDS and
simple analgesics, ergotamine derivatives, triptans, opioids, and combination analgesics.
Preventive medication classes included antidepressants, antiepileptics, beta-blockers, and
onabotulinumtoxinA (Botox). This measure can be found in Appendix C.
2.2.4 Headache Impact Test-6
The Headache Impact Test-6 (HIT-6; Kosinski et al., 2003) is a 6-item self-report
measure of the impact of headache on an individual’s functioning. The instrument addresses how
social functioning, cognitive functioning, and psychological distress are affected by headache.
Each question requires the respondent to provide an estimate of frequency of impairment (over
the last 4 weeks) on a 5-point Likert-type scale ranging from “never” to “always”. Scores range
from 36 to 78 and provide a basis for categorizing headache-related disability into 4 levels of
severity: little impact (scores ≤ 49), some impact (50-55), substantial impact (56-59), and very
severe impact (scores ≥ 60). The HIT-6 has shown good internal consistency (α= 0.90) and testretest reliability (r = 0.78) as well as discriminant validity across headache diagnostic groups
(Kosinski et al., 2003). This measure can be found in Appendix D.
2.2.5 Patient Health Questionnaire-9
The Patient Health Questionnaire-9 (PHQ-9; Kroenke, Spitzer, & Williams, 2001) is a 9item self-administered measure of depression severity based on DSM-IV diagnostic criteria.
Each question requires the respondent to provide an estimate of frequency of depressive
symptoms (over the past two weeks) on a 4-point Likert-type scale. Each item is rated from 0
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(not at all) to 3 (nearly every day). Scores range from 0 to 27 and provide a basis for categorizing
depressive symptoms into 4 levels of severity. Scores of 5, 10, 15, and 20 represent mild,
moderate, moderately severe, and severe depression, respectively. The PHQ-9 has shown good
construct validity (Kroenke et al., 2001), as well as adequate internal consistency pre- and posttreatment (α = .74 and .81) and convergent/divergent validity (Titov, Dear, McMillan, Anderson,
Zou, & Sunderland, 2011). Furthermore, meta-analytic data indicate that the PHQ-9 is externally
valid and able to correctly identify (sensitivity = 0.80) and rule-out (specificity = 0.92) majordepressive disorder across a wide range of settings and populations (Gilbody, Richards, Brealey,
& Hewitt, 2007). This measure can be found in Appendix E.
2.2.6 Generalized Anxiety Disorder 7-Item Scale
The Generalized Anxiety Disorder 7-Item Scale (GAD-7; Spitzer, Kroenke, Williams, &
Lowe, 2006) is a seven item self-administered measure of anxiety symptoms. Each item requires
respondents to rate the frequency of anxiety symptoms (over the past two weeks) on a 4-point
Likert-type scale that ranges from 0 (not at all) to 3 (nearly every day). Scores range from 0 to 21
and scores of 5, 10, and 15 represent mild, moderate, and severe anxiety symptoms, respectively.
The GAD-7 has excellent internal consistency (α= 0.92) and test-retest reliability (r = 0.83), as
well as convergent, construct, criterion, procedural, and factorial validity for the diagnosis of
generalized anxiety disorder (Spitzer et al., 2006). The GAD-7 also performs well as a screening
tool for other anxiety disorders such as post-traumatic stress disorder, panic disorder, and social
anxiety (Kroenke, Spitzer, Williams, Monahan, & Lowe, 2007). This measure can be found in
Appendix F.
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2.2.7 Pain Anxiety Symptoms Scale-Short Version
The Pain Anxiety Symptoms Scale (PASS-20; McCracken & Dhingra, 2002) is a
condensed 20-item version of the 40-item PASS (McCracken, Zayfert, & Gross, 1992). The
PASS-20 is a self-administered measure designed to assess FOP. Each item requires the
respondents to rate how frequently they engage in specific thoughts and behaviors related to the
experience of pain on a 6-point Likert-type scale that ranges from 0 (never) to 5 (always). The
PASS-20 is divided into four 5-item subscales that measure cognitive anxiety responses, escape
and avoidance, fearful thinking, and physiological anxiety responses. Subscale scores range from
0-25 and total scores range from 0-100. Individuals with scores greater than 30 are classified as
having high FOP (Abrams, Carleton, & Asmundson, 2007). The PASS-20 has shown excellent
internal consistency (α= 0.91; Abrams et al., 2007; McCracken & Dhingra, 2002), good testretest reliability (r = 0.68; Coons, Hadjistavropoulos, & Asmundson, 2004), as well as
concurrent validity with other related measures (Abrams et al., 2007). This measure can be found
in Appendix G.
2.2.8 Medication Use/Misuse Questionnaire
Similar to the measure used by Meisel and Goodie (2015), respondents were asked to
endorse whether they had a current prescription for the following non-headache medications:
stimulants (i.e., Ritalin, Adderall, Dexedrine), opioids (not for the treatment of headache; i.e.,
Vicodin, Oxycotin, Percocet), anxiolytics (i.e., Xanax, Valium, Klonopin), and sedatives (i.e.,
Ambien, Halcion, Restoril). Prescription misuse was assessed by asking respondents to endorse
whether they had used any of these medications without a prescription during the past 12

25

months. For each medication they endorsed misusing, participants were asked to endorse the
average number of days per month of use. This measure can be found in Appendix H.
2.2.9 Substance Use/Abuse Questionnaire
Similar to the measure used by Meisel and Goodie (2015), respondents answered
questions related to the frequency of their alcohol, tobacco, caffeine, and marijuana use during
the past 12 months. For each substance they endorsed, frequency of use was assessed by asking
respondents to report the average number of days per month of use. Respondents were also asked
whether they had used cocaine, methamphetamine, ecstasy, heroin, inhalants, or hallucinogens
during their lifetime. Additional items queried whether or not they had experienced symptoms of
dependence and whether they or a family member had been diagnosed or treated for a substance
use disorder. This measure can be found in Appendix I.
2.3 Procedure
Patients treated at Oxford Neurology Clinic consent to being contacted and having their
data used for research purposes as part of the clinic intake procedures. Medical chart reviews
were conducted on May, 24, 2016 by the chief neurologist in order to identify eligible
participants treated for headache within the past six years (e.g., between March, 1, 2010 – May,
24, 2016). Electronic records were searched using the following diagnostic terms: “druginduced”, “migraine”, “cluster”, “tension”, and “headache”. Between June 2016 and February
2017, all eligible patients who had email addresses on file were emailed an invitation to
participate in the study, and a random sample of patients without email addresses who had been
seen in the clinic since January, 1, 2012 were sent mailed invitations to participate. Each
invitation included a link to a computer-administered Qualtrics survey that included the
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aforementioned measures. When eligible participants visited the link, they were provided with
information about study procedures and associated risks and benefits. Prior to beginning the
survey, informed consent was obtained electronically. Patients who completed the questionnaire
received a $10 Amazon gift card for participating. Patients who reported that they no longer
suffered from headache were excluded from the study, as were patients who had less than 80%
complete data (in total and on each individual measure), failed to answer headache-relevant
items, or endorsed headache resulting from head injury/trauma.
2.7 Statistical Analysis
Analyses were conducted with SPSS 22.0 (IBM, Inc., Chicago, IL, USA). Descriptive
statistics are presented using frequency counts, percentages, means, and standard deviations.
Odds ratios (ORs) with 95% confidence intervals (CIs) and p-values are also presented for
interpretive convenience. To avoid the common problem of inflated Type 1 error rates often
associated with analyses involving numerous predictor variables, standardized mean differences
(SMDs; Austin, 2011) were calculated to quantify the size of any observed differences between
MOH and non-MOH groups. Standard mean difference functions as a measure of effect size
between groups that is calculated in relation to the two groups’ pooled variability (i.e., SD).
Similar to Cohen’s D (Cohen, 1992), SMDs of 0.2-0.49 are interpreted as small effects, 0.5-0.79
as medium effects, and ≥ 0.8 as large effects.
Combined theory- and data-driven approaches were used to examine the characteristics
independently (i.e., one predictor alone) and uniquely (i.e., after controlling for other predictors)
associated with MOH. To reduce the potential number of predictors into discrete subsets for
subsequent analyses, predictor variables were aggregated into five domains based on theoretical
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consistency: 1) demographic variables, 2) headache characteristics (including pain quality,
headache frequency, and headache-related disability), 3) psychiatric variables, and 4) headache
medication use, and 5) substance use variables. Next, a regression classification tree selection
strategy was utilized separately within each domain to identify the candidate predictors that best
differentiated between those with and without MOH. For this approach, the chi-square automatic
interaction detection (CHAID) algorithm (Kass, 1980) was used to select the optimal
combination of candidate predictors of MOH within each domain after adjusting the required
statistical significance by the number of candidate predictors in each domain with a Bonferroni
correction (p-value = .05/number of predictors within domain). The CHAID algorithm was
selected because it is a non-parametric recursive partitioning model that tests which predictor
variables are most strongly associated with a dichotomous outcome. As such, the CHAID
algorithm is an empirically-based means of selecting candidate predictors for inclusion in a
multivariate model.
Subsequently, all candidate predictors selected from each domain analysis were
simultaneously forced into a multivariable logistic regression model with MOH status as the
dichotomous outcome variable. The calibration of this model was assessed using a Hosmer and
Lemeshow test, and the predictive utility was assessed using the area under the curve (AUC) of a
calculated receiver operating characteristic curve. Because the final model was the result of
many data-driven inferences, the 95% CIs of the parameter estimates were re-estimated for
confirmation using bootstrapping of 500 samples of the dataset with replacement.
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3. RESULTS
3.1 Participant Demographics and MOH Prevalence
Two-thousand nine hundred and fifty-three eligible patients (i.e., adults with tension-type
headache, migraine, or cluster headache) were identified from the Oxford Neurology Clinic
database. A total of 1,656 patients were sent invitations to participate in the study, 646 via email
and 1,010 via mail. A total of 198 patients responded to the invitation (12.0% response rate).
Twenty patients failed to complete the entire survey and were excluded from analyses, as were
three patients who denied headache and 11 patients who reported headaches deriving from a
head injury or trauma.
The analyzed sample consisted of 164 headache patients (87.8% female) with a mean age
of 40.14 years (SD = 13.80). The majority (82.9%) of the sample was Caucasian, 14.6% were
African-American, 1.2% were Hispanic/Latino, 0.6% were Asian, and 0.6% identified as
multiracial. With regard to headache diagnosis, 43 patients (26.2%) met ICHD-III criteria for
MOH, 21 (12.8%) met criteria for CM without MOH, 6 (3.7%) met criteria for CTTH, 70
(42.7%) met criteria for EM (34 [20.7%] without aura and 36 [22%] with aura), 23 (14%) met
criteria for episodic tension-type headache, and 1 (0.6%) met criteria for cluster headache. On
average, participants reported experiencing headache 12.48 days per month (SD = 8.10), and
average headache severity for the sample was 6.42 out of 10 (SD = 1.78). Participants reported a
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mean score of 64.44 (SD = 6.76) on the HIT-6, with 79.3 % scoring at or above the cutoff for
very severe headache disability.
3.2 Determinants of MOH Status
3.2.1 Demographic Characteristics
As expected, the patients who met diagnostic criteria for MOH experienced more
headache days per month on average (20.58) in comparison to patients who did not meet criteria
for MOH (9.60; p < .001). Table 2 displays additional demographic characteristics of the sample
by MOH status. The two groups were evenly balanced (SMD < 0.15) on all demographics except
age, marital status, and BMI. On average, MOH patients were five years older (43.86 vs. 38.82;
SMD = 0.37), less likely to be married (18.6% vs. 33.9%; SMD = 0.30), and reported a greater
BMI (32.56 vs. 28.83; SMD = 0.48) relative to the non-MOH control group. Although age,
marital status, and BMI differentiated between the two diagnostic groups in the univariate
analyses, none of the demographic variables were significant within the classification tree model.
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Table 2. Participant Demographic Characteristics by MOH Status.
Predictor
Age
Gender
Male
Female
Ethnicity
White
Non-white
Marital Status
Married
Not Married
Education
< Bachelor’s
degree
≥ Bachelor’s
degree
Income
< $50,000
≥ $50,000
Employment
Employed
Unemployed
BMI

MOH (N = 43)
43.86 (14.65)

No MOH (N= 121)
38.82 (13.30)

5 (11.6%)
38 (88.4%)

15 (12.4%)
106 (87.6%)

36 (83.7%)
7 (16.3%)

100 (82.6%)
21 (17.4%)

8 (18.6%)
35 (81.4%)

41 (33.9%)
80 (66.1%)

23 (53.5%)
20 (46.5%)

56 (46.3%)

OR
1.03*
1.08

95% CI
1.00-1.05
0.37-3.16

SMD
0.37
0.06

1.08

0.42-2.76

0.08

0.45

0.19-1.05

0.30

0.75

0.37-1.51

0.13

0.81

0.39-1.65

0.09

0.88

0.43-1.79

0.06

1.06**

1.02-1.11

0.48

65 (53.7%)

26 (61.9%)
16 (38.1%)
24 (57.1%)
18 (42.9%)
32.56 (9.15)

68 (56.7%)
52 (43.3%)
73 (60.3%)
48 (39.7%)
28.83 (7.14)

Note. Values are frequency counts (%), except for age which is displayed as a mean (standard
deviation). MOH = medication-overuse headache, OR = odds ratio vs No MOH group, CI =
confidence interval, SMD = Standardized mean difference, BMI = body mass index.
*p < .05. **p < .01.
3.2.2 Headache Characteristics
Table 3 displays the headache characteristics between groups. A small effect was
observed between groups on headache severity (SMD = 0.46) and a medium effect was observed
in headache-related disability (SMD = 0.61). These univariate outcomes indicated that patients
with MOH experienced more severe headaches and greater headache-related disability in
comparison to non-MOH patients. In the classification tree, only headache-related disability
(HIT-6) scores significantly discriminated between groups, χ2 (1) = 17.64, p < .001. Moreover,
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the classification tree indicated that a HIT-6 score of 67 made the best distinction between the
two groups such that individuals who obtained scores greater than 67 on the HIT-6 were more
likely to meet criteria for MOH in comparison to individual who reported scores equal to or less
than 67. Selection of additional predictors within this domain did not significantly improve the
prediction afforded by headache-related disability alone.
Table 3. Headache characteristics by MOH Status.
Predictor
Headache Duration
< 4 hours
≥ 4 hours
Pain Quality
Throbbing
Tight Pressure
Headache Location
Unilateral
Bilateral
Nausea
Yes
No
Photophobia
Yes
No
Phonophobia
Yes
No
Aura Symptoms
Yes
No
Headache Severity
Headache Disability
(HIT-6)

MOH (N = 43)

No MOH (N = 121)

5 (11.6%)
38 (88.4%)

29 (24%)
92 (76%)

26 (60.5%)
17 (39.5%)

80 (66.1%)
41 (33.9%)

30 (69.8%)
13 (30.2%)

83 (68.6%)
38 (31.4%)

36 (83.7%)
7 (16.3%)

88 (72.7%)
33 (27.3%)

41 (95.3%)
2 (4.7%)

104 (86%)
17 (14%)

41 (95.3%)
2 (4.7%)

107 (88.4%)
14 (11.6%)

27 (62.8%)
16 (37.2%)
7.02 (1.47)
67.60 (6.00)

62 (51.2%)
59 (48.8%)
6.21 (1.83)
63.31 (6.68)

OR
2.40

95% CI
0.86-6.65

SMD
0.27

1.28

0.62-2.62

0.10

0.95

0.45-2.02

0.02

1.93

0.78-4.76

0.23

3.35

0.74-15.16

0.26

2.68

0.58-12.32

0.21

1.61

0.79-3.28

0.21

1.34*
1.12**

1.07-1.69
1.05-1.20

0.46
0.61

Note. Values are frequency counts (%), except for headache severity and headache disability
which are displayed as a mean (standard deviation). MOH = medication-overuse headache, OR =
odds ratio vs No MOH group, CI = confidence interval, SMD = Standardized mean difference,
HIT-6 = Headache Impact Test-6.
*p < .05. **p < .01.
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3.2.3 Psychiatric Symptoms
Table 4 displays scores on the self-report measures of psychiatric symptoms by
diagnostic status. A medium-sized effect was observed on PHQ-9 (SMD = 0.64), as patients with
MOH reported moderate levels of depressive symptomatology compared to those without MOH,
who instead on average reported mild levels of depressive symptomatology. Furthermore, a
small between-group difference was observed on the GAD-7 (SMD = 0.46), such that patients
with MOH reported more severe symptoms of relative to individuals who did not meet
diagnostic criteria for MOH. Medium differences (SMDs = 0.54-0.78) were also obtained for all
four PASS-20 subscales. Relative to treatment-seeking patients who did not meet criteria for
MOH, patients in the MOH group reported higher levels of cognitive anxiety (15.93 vs. 11.38),
escape and avoidance behaviors (14.64 vs. 10.44), fearful appraisals (8.26 vs. 4.96), and
physiological anxiety (10.49 vs. 7.33). For this domain, the PASS-20 escape and avoidance
subscale was the only variable selected in the classification tree as a significant predictor of
MOH status, χ2 (1) = 19.24, p < .001. The classification tree indicated that a PASS-20 escape and
avoidance subscale score of 12 made the best distinction between the two groups.
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Table 4. Self-reported Psychiatric Symptoms by MOH Status.
MOH (N = 43) No MOH (N = 121)
OR
95% CI
12.63 (6.76)
8.31 (6.71)
1.09**
1.04-1.15

Predictor
PHQ-9 Total
Score
GAD-7 Total
Score
PASS-20 Total
Score
Cognitive
Anxiety
Subscale
Escape &
Avoidance
Subscale
Fear
Appraisal
Subscale
Physiological
Anxiety
Subscale

SMD
0.64

9.30 (6.08)

6.55 (5.95)

1.08*

1.02-1.14

0.46

50.14 (18.92)

34.11 (20.96)

1.04***

1.02-1.06

0.78

15.93 (6.52)

11.38 (7.00)

1.10**

1.04-1.17

0.66

14.64 (5.36)

10.44 (6.13)

1.12***

1.05-1.19

0.71

8.26 (5.62)

4.96 (4.96)

1.12**

1.05-1.19

0.64

10.49 (6.31)

7.33 (5.68)

1.09**

1.03-1.16

0.54

Note. Values are displayed as a mean (standard deviation). MOH = medication-overuse
headache, OR = odds ratio vs No MOH group, CI = confidence interval, SMD = Standardized
mean difference, PHQ-9 = Patient Health Questionnaire-9, GAD-7 = Generalized Anxiety
Disorder 7-Item Scale, PASS-20 = Pain Anxiety Symptoms Scale-Short Version.
*p < .05. **p < .01. ***p < .001.
3.2.4 Medication Use
Rates of headache medication use by diagnostic status are displayed in Table 5. None of
the patients included in the sample reported the use of ergotamine for the treatment of headache.
However, meaningful differences between groups were observed for the use of many of the acute
headache medications. In comparison to non-MOH controls, patients who met diagnostic criteria
for MOH were more likely to use NSAIDs (72.1% vs. 60.3%), opioids (25.6% vs. 11.6%), antidepressants (32.6% vs. 18.2%), and beta-blockers (23.3 vs. 7.4%) for the treatment of headache.
Patients who met diagnostic criteria for MOH were also more likely to have received a Botox
treatment within the past six months (27.9% vs. 14.0%) in comparison to non-MOH controls. A
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medium-sized difference (SMD = 0.51) was observed for the use of combination medications
(e.g., acetaminophen/aspirin/caffeine, codeine with acetaminophen, hydrocodone with
acetaminophen), with 60.5% of MOH patients reporting use of these medications in comparison
to 33.1% of patients who did not meet criteria for MOH. Of these differences, only the use of
combination medications was selected into the classification tree to discriminate between the
groups χ2 (1) = 9.10, p = .002.

Table 5. Self-reported Headache Medication Use by MOH Status.
Predictor
MOH (N = 43) No MOH (N = 121)
OR
95% CI
NSAIDs
31 (72.1%)
73 (60.3%)
1.70
0.80-3.63
Triptans
18 (41.9%)
60 (49.6%)
0.73
0.36-1.48
Opioids
11 (25.6%)
14 (11.6%)
2.63*
1.09-6.35
Combination
26 (60.5%)
40 (33.1%)
3.10**
1.51-6.36
Medications
Botox
12 (27.9%)
17 (14.0%)
2.37*
1.02-5.49
Anti-depressants
14 (32.6%)
22 (18.2%)
2.17
0.99-4.78
Beta-blockers
10 (23.3%)
9 (7.4%)
3.77** 1.41-10.05
Anti-epileptics
14 (32.6%)
31 (25.6%)
1.40
0.66-2.99

SMD
0.22
0.14
0.35
0.51
0.32
0.31
0.45
0.14

Note. Values are frequency counts (%). MOH = medication-overuse headache; OR = odds ratio
vs No MOH group; CI = confidence interval; SMD = Standardized mean difference, NSAIDs =
nonsteroidal anti-inflammatory drugs.
*p < .05. **p < .01.
3.2.5 Substance Use
Rates of prescription medication use and substance use are displayed in Table 6. Very
few patients reported the misuse of medications prescribed for the treatment of medical
conditions other than headache. A total of four patients reported that they used opioids
prescribed for conditions other than headache without a physician’s prescription. In addition, six
patients reported the misuse of anxiolytics and two patients reported the misuse of sedatives.
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Given that the rate of medication misuse was so low, between-group comparisons were not
conducted for medication misuse variables.
In addition to low rates of prescription medication misuse, patients included in the sample
reported low rates of illicit drug use. The majority of patients (n = 156) reported that they had not
used illicit substances other than marijuana at any point in their life. Of the patients who
endorsed illicit drug use, five patients reported cocaine use, two patients reported crack cocaine
use, three patients reported methamphetamine use, two patients reported ecstasy use, two
patients reported inhalant use, and four patients reported hallucinogen use at some point during
their lifetime. In terms of substance use disorder (SUD) symptomatology, three patients reported
that they were unable to stop using substances when they wanted to and three patients reported
that they experienced withdrawal symptoms after they stopped using a substance at some point in
their life. Once again, between-group comparisons were not conducted for illicit substance use
variables other than marijuana because symptoms of SUD were infrequently reported by patients
included in the sample.
Although medication misuse and a personal history of illicit substance use were very rare
in the current sample, significant proportions of patients reported the prescribed use of
medications for other medical conditions, a family history of substance abuse, and/or the use of
alcohol, tobacco, caffeine, and cannabis. Accordingly, between-group analyses were conducted
for prescription drug use, a family history of substance abuse, and the use of alcohol, tobacco,
caffeine and cannabis. Small but meaningful differences (SMD = 0.20-0.28) between groups
were observed in current prescriptions for opioids for conditions other than headache, current
prescriptions for anxiolytics, and a family history positive for SUD. As such, patients who met
diagnostic criteria for MOH were more likely to be prescribed opioids for pain conditions other
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than headache (9.3 vs. 4.1%), have a current prescription for anxiolytics (30.2 vs. 17.4%), and to
have a family member with a SUD (32.6% vs. 19.8%) in comparison to patients who did not
meet criteria for MOH. Despite these small univariate differences, none of the substance use
variables were independently selected as significant predictors of MOH status in the
classification tree model.
Table 6. Self-Reported Substance Use by MOH Status.
Predictor
MOH (N = 43) No MOH (N = 121)
OR
95% CI
Stimulant Rx
3 (7.0%)
10 (8.3%)
0.83
0.22-3.18
Opioid Rx (not for
4 (9.3%)
5 (4.1%)
2.38
0.61-9.31
Headache)
Anxiolytic Rx
13 (30.2%)
21 (17.4%)
2.06
0.92-4.61
Sedative Rx
8 (18.6%)
14 (11.6%)
1.75
0.68-4.51
Alcohol Use (past 12
24 (55.8%)
75 (62.0%)
0.78
0.38-1.57
months)
Tobacco Use (past 12
9 (20.9%)
27 (22.3%)
0.92
0.39-2.16
months)
Caffeine Use (past 12
42 (97.7%)
112 (92.6%)
3.38 0.42-27.46
months)
Cannabis Use (past 12
2 (4.7%)
11 (9.1%)
0.49
0.10-2.30
months)
Family History of SUD
14 (32.6%)
24 (19.8%)
1.95
0.90-4.25

SMD
0.04
0.20
0.28
0.18
0.11
0.03
0.19
0.15
0.27

Note. Values are frequency counts (%). MOH = medication-overuse headache, OR = odds ratio
vs No MOH group, CI = confidence interval, SMD = Standardized mean difference, Rx =
Prescription, SUD = substance use disorder.
3.3 Final Multivariable Model
Table 7 displays the three selected predictors (headache-related disability, escape and
avoidance subscale of the PASS-20, and the use of combination medications for the treatment of
headache) that were forced into the final multivariable model using the classification tree
approach, along with 95% CIs as estimated through bootstrapping using 500 samples with
replacement. The omnibus model differentiated well between the two diagnostic groups χ2(3) =
28.86, p <.001, and the Hosmer-Lemeshow test confirmed an absence of differences between
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observed and predicted participant classifications χ2(8) = 3.66, p = .887. Figure 1 graphically
displays the predictive utility of this 3-variable model, which had an AUC = 0.78 (95% CI =
0.71–0.86). Headache disability and the consumption of combination medications for the
treatment of headache were uniquely associated with MOH diagnosis after controlling for the
other predictors and after bootstrapping confirmation. Specifically, patients prescribed
combination medications for the treatment of headache were approximately three times as likely
to have MOH as patients who were not prescribed these medications. Likewise, odds of meeting
diagnostic criteria for MOH increased 9% for each 1-point increase on the HIT-6. Further, the
effect of the PASS-20 fell just short of significance after controlling for the other predictors
included in the final model. For every 1-point increase on the PASS-20 escape and avoidance
scale, odds of meeting diagnostic criteria for MOH increased by 7%.

Predictor
Headache Disability
(HIT-6)
PASS-20 Escape &
Avoidance Score
Combination
Medications

Table 7. Final Multivariable Prediction Model
Bootstrapped
OR
95% CI
β
95% CI

p-value

0.09

0.17-0.21

1.09

1.01-1.18

.022

0.07

0.01-0.15

1.07

1.00-1.15

.051

1.13

0.37-1.98

3.09

1.42-6.73

.004

Note. Omnibus model χ2(3) = 28.86, p <.001, Hosmer-Lemeshow χ2(8) = 3.66, p = .887,
bootstrapped estimate from 500 sample replications. β = estimated multinomial logistic
regression coefficient, CI = confidence interval, HIT-6 = Headache Impact Test-6, PASS-20 =
Pain Anxiety Symptoms Scale-Short Version.
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Figure. 1. Receiver operating characteristics (ROC) curve of multivariable prediction model of
medication-overuse headache status. Area under the curve: 0.78 (95% confidence interval 0.710.86), p < .001.
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4. DISCUSSION
The present cross-sectional analysis is among the first to examine the comparative
importance of factors associated with MOH among treatment-seeking headache sufferers in the
United States. In this sample, the factors most strongly associated with MOH included headacherelated disability, attempts to escape and avoid painful stimuli, and the use of combination
medications for the treatment of headache. In conjunction, these three variables accurately
distinguished between those with and without MOH.
4.1 Demographic and Headache Characteristics
Contrary to hypotheses, women were no more likely than men to meet diagnostic criteria
for MOH. These findings suggest that demographic characteristics may not be particularly
relevant to the identification of headache patients who are currently overusing acute pain
medications. Although some studies have found that women are more likely to develop MOH
(Jonsson et al., 2011), others have suggested that the preponderance of women with MOH
simply reflects the fact that women are much more likely than men to suffer from headache
(Burch et al., 2015; Westergaard et al., 2014). The findings of the current study support the latter
conclusion and suggest that headache treatment history, behavioral responses to pain, and
psychiatric variables are more relevant in the identification of patients with medication overuse.
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Patients with a history of migraine typically experience unilateral pulsating pain (ICHDIIIβ), and previous research suggests that patients with MOH typically report a history of
migraine (Mathew, 1982; Radat et al., 2008). Although patients with TTH may also overuse
acute headache medications, TTH is less frequently associated with MOH in comparison to
migraine (Silberstein et al., 1996). Despite the association between migraine and MOH, pain
quality and location frequently change following the onset of MOH (Tepper, 2012) and may
differ by medication type (Limmroth et al., 2002). Thus, it is more difficult to identify the
primary headache diagnosis while the patient continues to overuse acute headache medications
(Diener, Holle, Solbach, & Gaul, 2016). In contrast to previous studies that identified headache
characteristics and diagnoses most closely associated with the development of MOH, the current
study examined whether headache characteristics could differentiate between patients with MOH
and non-MOH controls. Results indicated that patients with MOH did not differ significantly
from non-MOH controls in terms of pain location or quality. Thus, patients who report unilateral
pulsating migraine pain may be more likely to develop MOH relative to TTH patients who report
bilateral tightening pain; however, headache characteristics such as pain quality and location do
not appear to reliably differentiate between patients already with MOH and those without MOH.
4.2 Headache-Related Disability
The finding that headache patients who met criteria for MOH were significantly more
disabled in comparison to non-MOH control patients adds to a large body of research indicating
that MOH is significantly more disabling than most other forms of headache (Lanteri-Minet et
al., 2011; Linde et al., 2012; Raggi et al., 2015). In addition to previous estimates of the societal
burden and monetary cost associated with MOH (D’Amico et al., 2005; Linde et al., 2012; Vos
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et al., 2013), the present findings highlight the personal costs associated with MOH. Specifically,
individuals with MOH are more likely to experience negative cognitive, social, and
psychological outcomes in comparison to patients seeking treatment for other headache
conditions. In the univariate analysis, individuals with MOH reported HIT-6 scores that were
4.29 points higher on average relative to non-MOH controls. Moreover, the multivariable model
indicated that for every 1-point increase on the HIT-6, the odds of meeting criteria for MOH
increased by 9%, even after controlling for scores on the escape and avoidance subscale of the
PASS-20 and the use of combination medications. Extrapolating this finding using the four
levels of severity specified by the HIT-6, an individual who scored a 60 on the HIT-6 (e.g., “very
severe” headache-related disability) was at approximately two times greater odds of meeting
diagnostic criteria for MOH in comparison to an individual who scored a 49 on the HIT-6 (e.g.,
“little impact” of headache on disability). Although HIT-6 scores were associated with MOH,
headache-related disability is conceptualized as a consequence of MOH (Linde et al., 2012)
rather than a predictor of maladaptive medication use behaviors. Therefore, headache-related
disability is rarely conceptualized as a risk factor for MOH. As such, the HIT-6 and other brief
measures of headache-related disability may be most useful for identifying patients who are
currently overusing their headache medications and for monitoring treatment progress.
4.3 Escape and Avoidance Behaviors
Although previous studies have indicated that repeated engagement in escape and
avoidance behaviors in the presence of pain-related stimuli is associated with increased disability
and the use of acute headache medications (Asmundson et al., 2001; Black et al., 2015), the
present study is among the first study to examine FOP as a predictor of MOH using ICHD-IIIβ
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diagnostic criteria. Patients who met diagnostic criteria for MOH were more likely to engage in
escape and avoidance behaviors (e.g. avoiding important activities due to pain, cessation of
activities at the first sign of pain, and taking medications at the first sign of pain) relative to
patients with other headache conditions. Individuals with MOH obtained PASS-20 escape and
avoidance subscale scores that were on average 4.20 points greater than those of non-MOH
controls. Moreover, the multivariable model indicated that for every 1-point increase on the
PASS-20 escape and avoidance subscale, the odds of meeting criteria for MOH increased by 7%,
even after controlling for headache-related disability and the use of combination medications.
The finding that pain-related escape and avoidance is strongly associated with MOH has
significant clinical implications. Historically, headache patients have been advised to identify
and avoid headache triggers (World Health Organization, 2006). Presumably, this advice is given
under the notion that avoidance of triggers should confer reduction in headache. However, there
is very little empirical or theoretical support for this strategy (see Martin & MacLeod, 2009).
Instead, a prolonged pattern of escape and avoidance in response to headache triggers and
headache pain is often maladaptive and associated with a number of negative consequences
stemming from increased sensitivity to the avoid trigger, including increased pain, disability, and
the excessive use and misuse of analgesics (Asmundson et al., 1999; Asmundson et al., 2001;
Black et al., 2015; McCracken & Dhingra, 2002; Norton & Asmundson, 2004; Vlaeyen et al.,
1995). Based on these findings and psychological research in the area of stress and emotion
regulation (Meichenbaum, 1985; Blackledge & Hayes, 2001), an emerging body of research
suggests that progressive exposure to triggers, similar to that used for the treatment of anxiety
disorders, is effective in reducing nociceptive response and sensitivity to headache triggers
(Martin, 2001; Martin, Lae, & Reece, 2007; Martin, Reece, & Forsyth, 2006). In these studies,
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individuals were exposed to commonly identified headache triggers (e.g., “visual disturbances”,
noise, and stress) for varying durations. In all three studies, a curvilinear relationship was
identified between the length of exposure to a trigger and sensitivity to the trigger, such that
longer exposure produced decreased sensitivity. Based on these findings, a recent randomized
controlled trial (RCT) found that a behavioral intervention that included graduated exposure to
relevant headache triggers produced significant improvements in headache and reductions in
medication consumption (Martin et al., 2014). In conjunction with these findings, the current
study suggests that headache patients who are highly fearful of pain may engage in consistently
avoidant patterns of behavior and are thus more likely to meet diagnostic criteria for MOH.
Exposure-based treatment, such as that developed by Martin and colleagues (2014), may hold
particular promise for individuals who are highly fearful of pain and patients who meet
diagnostic criteria for MOH. Nonetheless, carefully controlled research is needed before such
conclusions can be drawn.
4.4 Other Psychiatric Symptoms
Although the escape and avoidance subscale of the PASS-20 was the only psychiatric
variable chosen for inclusion by in the classification tree, several other measures of psychiatric
symptoms were significantly associated with MOH status in univariate analyses. As reported
elsewhere (Hagen et al., 2012; Radat et al., 2005), anxiety and depression are associated with
subsequent development of MOH and may serve as predictors for deleterious outcomes.
Consistent with these findings, patients in the present study who met diagnostic criteria for MOH
obtained scores on the PHQ-9 and GAD-7 significantly greater than those of patients without
MOH. Though is well established that psychiatric disorders are commonly comorbid with
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headache (Kalayadjian & Merikangas, 2008), findings of this and other studies indicate that
psychiatric comorbidities are even more prevalent among individuals with MOH. For example,
Radat and colleagues (2005) found that individuals suffering from MOH were more likely to
report anxiety and mood disorders in comparison to migraineurs, and that these conditions were
far more likely to precede than to follow MOH. As such, psychiatric conditions are
conceptualized risk factors for MOH rather than the result of MOH. The self-medication model
of substance use disorders (Khantzian, 1997) suggests that individuals abuse substances in an
attempt to avoid, escape, or relieve distress evoked by negative affective states. Accordingly,
future studies should examine to what extent this model applies to individuals with MOH and
whether behavioral and cognitive-behavioral interventions (e.g., exposure-based interventions
for anxiety and behavioral activation for depression) targeting anxiety and depression are
effective for preventing the development of MOH or reducing the frequency of acute medication
use.
4.5 Medication Use
As predicted, use of medications with higher potential for abuse and misuse (e.g. opioids
and combination medications, which included those containing opioids) was associated with
higher odds of meeting criteria for MOH. Although use of opioid medications significantly
predicted MOH in univariate analyses, the use of combination medications was the strongest
predictor of MOH status, and use of opioids did not improve the classification afforded by use of
combination medications. After controlling for headache-related disability and escape and
avoidance behaviors, patients using combination medications were still at approximately three
times greater odds to meet the diagnostic criteria for MOH relative to patients not using these
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medications. The current findings support the recommendation that opioids and opioidcombination analgesics should generally not be prescribed for headache (Loder et al., 2013). All
acute headache medications have the potential for overuse; however, headache-specific
medications such as triptans and non-specific medications such as NSAIDS were associated with
much lower odds (0.73 and 1.70, respectively) for MOH.
Combination medications that contain NSAIDs have demonstrated consistent and
impressive evidence for the treatment of migraine (Gatoulis, Voelker, & Fisher, 2012; Loder,
2005). However, many authors suggest that opioid-combination analgesics should be used on a
limited basis (Levin, 2014; Loder, 2005; Loder et al., 2013). Although many opioids and opioidcombination analgesics are superior to placebo for the treatment of headache (Kelley & Tepper,
2012; Loder, 2005), the frequent use of opioids and opioid-combination analgesics for the
treatment of headache pain is contraindicated due to a high risk for headache chronification, pronociceptive effects, tolerance, overuse, and addictive behaviors, as well as decreased
effectiveness of other acute medications (Bigal et al., 2008; Katzung, Masters, & Trevor, 2012;
Levin, 2014; Kelley & Tepper, 2012). For example, Bigal and colleagues (2008) documented the
association between opioid use and the rapid progression of migraine even for minimal use.
Similar concerns have been raised in reference to the use of opioid-combination analgesics, as
the regular use of opioid-combination analgesics is associated with chronic headache (Scher et
al., 2010). Accordingly, more research regarding the safety and tolerability of these drugs is
warranted. Given the sparse evidence for efficacy and the high risk for tolerance and overuse,
opioids and opioid-combination analgesics should only be used the treatment of headache when
all other options have been exhausted. Practice guidelines and recommendations promote triptans
for patients who respond poorly to NSAIDS and daily preventive medications for patients who
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overuse their acute headache medications (Loder et al., 2013). The findings of the current study
add to concerns regarding the efficacy and safety of combination medications as patients who
used these medications were at a more than a three times greater risk for MOH in comparison to
patients who did not use these medications.
The fact that the use of opioids for the treatment of headache was not chosen for
inclusion in the final multivariable model was unexpected and may be at least partially
attributable to the small number of patients (n = 25) who reported the use of opioids for the
treatment of headache. Relative to population samples that include patients treated in a variety of
settings, patients recruited for the present study may have been less likely to receive a
prescription for opioids because they were receiving treatment from a headache specialist
familiar with headache treatment guidelines. Ongoing research efforts are needed to monitor and
examine prescription practices across a wide variety of settings. Specifically, a focus on ED
settings seems prudent as opioids remain commonly prescribed in these settings (MazerAmirshahi et al., 2014; McCarthy & Cowan, 2015) and may reflect prescribers’ unfamiliarity
with headache treatment guidelines. In addition to well-documented legislation and public health
reform, efforts aimed at curbing the prescription of opioids for chronic pain, additional efforts
should be aimed at making headache treatment guidelines readily available in ED settings.
4.6 Substance Use
Contrary to expectations, substance use and prescription misuse were relatively
uncommon and did not differentiate between patients who met diagnostic criteria for MOH and
those who did not. The relationship between MOH and problematic substance use is unclear and
complex. Medication overuse headache has previously been depicted as a part of a broader
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pattern of substance abuse and addictive behaviors (Radat et al., 2008; Radat et al., 2005).
Patients with MOH have exhibited higher rates of abuse and misuse of substances such as
tobacco, caffeine, sedatives, and anxiolytics; however, only a small percentage of individuals
reported problematic alcohol use or illicit drug use (Hagen et al., 2012; Radat et al., 2008; Radat
et al., 2005). In light of the current findings and findings drawn from previous research, the
function of substance use and medication misuse behaviors should be examined further among
individuals with headache. Although some headache patients may engage in problematic
substance use and medication misuse with the goal of “getting high”, it may be the case that the
majority of headache patients overuse analgesics and use other substances in an attempt to selfmedicate headache pain and psychiatric distress. The finding that there was no association
between MOH and problematic alcohol use or illicit drug use is consistent with previous findings
(Hagen et al., 2012; Westergaard et al., 2016). A significant proportion of headache patients
abstain from alcohol (Panconesi, Franchini, Bartolozzi, Magnai, & Guidi, 2013), possibly
because alcohol is among the most commonly identified dietary headache triggers (Kelman,
2007). Despite these findings, medication class should be examined a moderator of this
relationship. A large number of patients included in the present study overused over-the-counter
medications, but problematic substance use has been documented most extensively among
chronic pain patients who misuse opioids (Ives et al., 2006).
4.7 Limitations and Future Directions
Strengths of the current study included the examination of a treatment-seeking sample of
headache patients, the consideration of relevant MOH risk factors in conjunction, and the use of
a conservative and empirical approach designed to avoid Type I error inflation when selecting
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variables for the final multivariable model. Despite these strengths, some limitations are worth
bearing in mind. First, the present study was cross-sectional; therefore, significant associations
between variables should be interpreted as correlational rather than causal due to uncertainty
regarding the temporal ordering of variables. For example, it is assumed that psychiatric
symptoms predict medication overuse (Radat et al., 2005; Schmid et al. 2013) and negatively
influence pain coping abilities (Asmundson et al., 2001; Black et al., 2015). However, we did not
assess order of occurrence, and psychiatric symptoms could develop or worsen subsequent to the
overuse of acute headache medications. The temporal ordering of variables has significant
theoretical implications as the function of medication overuse is often ignored. Based on
theoretical models such as the fear-avoidance model of chronic pain (Vlaeyen & Linton, 2000)
and the self-medication model of substance use disorders (Khantzian, 1997), headache patients
who overuse their medications may do so in an attempt to avoid pain and feared pain-related
stimuli or to self-medicate symptoms of anxiety and depression. However, causality cannot be
assumed until this study is replicated longitudinally. Studies that concurrently monitor headache
frequency, medication use, psychiatric symptoms, and other medical and psychosocial variables
over time would provide valuable data related to the directionality and causality of relationships
between variables and could inform the development of future assessment measures and
intervention efforts.
Second, though the sample was unique in that it was composed of individuals seeking
treatment for headache, patients were all treated by the same physicians and drawn from a
limited geographic area. Despite this limitation, the rate of MOH in the present study
(approximately 26%) closely resembles that from previous studies (Schmid et al., 2013).
Individuals who met criteria for MOH also reported 20.58 (SD = 5.39) headache days per month
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on average and were very severely impaired due to headache pain. Thus, the nature of their
headache characteristics also closely resemble treatment-seeking samples used in previous
studies (Schmid et al., 2013; Usai, Grazzi, D’Amico, Andrasik, & Bussone, 2008). In
conjunction, the similarity between the present and prior samples increases confidence that the
current findings are likely generalizable to clinical samples of headache patients. Nonetheless,
replication efforts are needed with more diverse patients drawn from a variety of locations and
clinics.
Third, assessment of substance use and medication misuse was limited in two ways. First,
substance use and medication use variables were based solely on self-report, and biological
measures were not collected. As part of informed consent, patients were instructed that their
responses would remain entirely confidential and would not impact the treatment that they
received from their healthcare provider. Nonetheless, patients may have been reluctant to
disclose information related to the use of illicit substances or the misuse of prescription
medications. Second, in order to reduce the burden on participants and increase participation in
the study, a large number of headache medications were collapsed into a smaller number of
categories. For example, combination medications consisted of over-the-counter medications
such as Excedrin and highly potent opioid-combination medication such as Lortab. Given the
risks associated with the use of opioids for headache (Levin, 2014), there are likely to be
differences between individuals who overuse acetaminophen combinations and individuals who
overuse opioid-combination medications. Thus, future studies should consider more precise and
specific definitions of medication class and utilize biological markers of illicit drug use and
prescription medication misuse.
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Finally, low base rates of medication misuse and substance abuse limit the conclusions
that can be drawn with regard to the relation between these specific agents and MOH. Similarly,
univariate analyses did not reveal any significant interactions between examined variables.
Sample size constraints may have prohibited the assessment of interactive effects with sufficient
power. Despite the absence of significant interaction effects with this class of predictors, the
CHAID algorithm afforded valuable empirically-based decisions regarding which variables to
include in the multivariate model. Statistical approaches similar to CHAID algorithm
implemented in the present study may prove useful in the development of brief screening
measures that can be readily administered in busy primary care and emergency care settings.
Such measures could endeavor to include the three variables retained in the final multivariable
model herein and could also be helpful for identifying patients who would benefit from
preventive treatment efforts.
In summary, the current study is a first step in an effort to more effectively identify and
treat headache patients who are overusing prescription pain medications. Based on these
findings, a relatively focused number of variables can be assessed to identify patients most likely
to meet diagnostic criteria for MOH. Although a great deal of research has been aimed at
developing screening measures to identify patients at risk for opioid abuse and misuse in broader
populations (Butler, Budman, Fernandez, Franciullo, & Jamison, 2009; Butler, Budman,
Fernandez, & Jamison, 2004; Webster & Webster, 2005), MOH has received less attention.
Future studies may build on the present study by applying similar analytic approaches
longitudinally in order to identify headache patients at risk for medication overuse prior to the
onset of maladaptive medication use behaviors. In addition to the development of screening
measures, the findings that escape and avoidance behaviors were strongly predictive of MOH has
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significant clinical implications as headache patients are often instructed to avoid headache
triggers whenever possible. Future research should also examine whether exposure-based
treatments that facilitate engagement with headache triggers and other feared headache stimuli
can reduce the risk for MOH and whether previously developed interventions (Martin et al.,
2014) can be modified and abbreviated for effective implementation in clinical settings where
these challenging patients are commonly treated.
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DEMOGRAPHIC QUESTIONNAIRE
Please tell us a little bit about yourself. This information is of course completely confidential.
How old are you (in years)?:__________
Gender:__________ (male/female/trans)
Race: (check one)
______ Caucasian
______ Black/African-American
______ Hispanic/Latino
______ Asian
______ Asian or Pacific Islander
______ Native American or Alaskan Native
______ Native Hawaiian or Pacific Islander
______ Multiracial
What was your highest level of education? (check one)
______ 8th grade or less
______ some high school
______ high school diploma
______ some college/university
______ bachelor’s degree
______ master’s degree
______ doctoral or professional degree
Marital status: (check one)
______ single (never married)
______ married
______ divorced
______ separated
______ widowed
Employment status: (check one)
______ unemployed
______ home maker
______ part time
______ full time
Yearly household income: (check one)
______ < $10,000
______ $10,000 - $20,000
______ $21,000 - $30,000
______ $31,000 - $50,000
______ $51,000 - $100,000
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______ >$100,000
How tall are you? (in feet AND inches): ______Feet & ______Inches
How much do you weigh (in pounds)?: _____Pounds
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STRUCTURED DIAGNOSTIC INTERVIEW FOR HEADACHE – 3
1. Do you ever get headaches?
a. Yes
b. No
2. On average, how many DAYS PER MONTH do you have a headache (enter one number
between 0 and 30)?
_____ days per month with headache
3. If 0 is no pain, 5 is moderate pain, and 10 is the worst pain imaginable, what is the average
pain intensity of these headaches (enter one number between 0 and 10)?
_____ average pain intensity
4. If left untreated or unsuccessfully treated, about how long would these headaches usually last?
a. less than 30 minutes
b.at least 30 minutes but less than 2 hours
c.at least 2 hours but less than 4 hours
d. between 4 hours and 3 days
e. between 3 days and 7 days
f. longer than 7 straight days
5. For approximately how long have you been having these headaches?
a. Less than 3 months
b. 3 months
c. 4 months or more
6. About how many of these headaches have you had in your life?
a. Less than 5
b. 5 – 9
c. 11 – 20
d. More than 20
7. Which of the following best describes your pain?
a. Pulsating/Throbbing
b. Tight pressure (non-pulsating)
8. Is the pain typically experienced on one side or both sides of your head?
a. Typically one side
b. Typically both sides
9. Is the pain made worse by routine physical activities or cause you to avoid routine physical
activities (like walking, bending over, or climbing stairs)?
a. Yes
b. No
10. Do you often feel nauseous or sick to your stomach during these headaches?
a. Yes
b. No
11. Do you often vomit or throw up during these headaches?
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a. Yes

b. No

12. Are you often sensitive to light during these headaches?
a. Yes
b. No
13. Are you often sensitive to sound during these headaches?
a. Yes
b. No
14. Do you often experience any symptoms shortly before the headache pain actually begins,
such as changes in your vision (blurry vision, seeing spots or zigzag lines), changes in your
sensation (numbness, tingling), or changes in your speech?
a. Yes
b. No
15. How many times have you experienced these symptoms before having a headache?
a. 1
b. 2 – 5
c. 6 – 10
d. More than 10
16. Do you use any medications to treat these headaches?
a. Yes
b. No
17. How many days per week do you use any type of medication to treat your headaches?
a. Less than 1 day per week
b. 1-2 days per week
c. 3 days per week
d. 4 or more days per week
18. How long have you been using these medications at this frequency?
a. 3 months or less
b. More than 3 months
19. Did your headache develop or get worse when you started using these medications at this
frequency?
a. Yes
b. No
20. Did this headache develop shortly after a head injury or head trauma?
a. Yes
b. No
21. Have you ever been diagnosed with cluster headaches?
a. Yes
b. No
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HEADACHE MEDICATION USE QUESTIONNAIRE
1. Are you currently taking NSAIDS or simple analgesics (e.g. aspirin [Bayer, Excedrin],
ibuprofen [Advil, Motrin], naproxen sodium [Aleve], Anaprox) for the treatment of your
headaches?
a. How many days during the previous month did you use NSAIDS or simple analgesics for
the treatment of your headaches?
b. How long have you used NSAIDS or simple analgesics at this frequency?
2. Are you currently taking ergotamine for the treatment of your headaches?
a. How many days during the previous month did you use ergotamine for the treatment of
your headaches?
b. How long have you used ergotamine at this frequency?
3. Are you currently taking triptans (e.g. sumatriptan [Imitrex], naratriptan [Amerge],
zolmitriptan [Zomig], rizatriptan [Maxalt], almotriptan [Axert], frovatriptan [Frova],
eletriptan [Relpax]) for the treatment of your headaches?
a. How many days during the previous month did you use triptans for the treatment of your
headaches?
b. How long have you used triptans at this frequency?
4. Are you currently taking opioids (e.g. codeine, hydrocodone, merperdine [Demerol],
oxycodone [Oxy IR], dilaudid, morphine) for the treatment of your headaches?
a. How many days during the previous month did you use opioids for the treatment of your
headaches?
b. How long have you used opioids at this frequency?
5. Are you currently taking combination medications (e.g. acetaminophen/aspirin/caffeine
[Excedrin Migraine, BC Powder, Goody’s Powder], codeine with acetaminophen [Tylenol
#3], hydrocodone with acetaminophen [Lortab, Vicodin], merperdine with promethazine
[Mepergan], oxycodone with aspirin [Percodan], oxycodone with acetaminophen [Percocet]
for the treatment of your headaches?
a. How many days during the previous month did you use combination medications for the
treatment of your headaches?
b. How long have you used combination medications at this frequency?
6. Are you currently taking antidepressants (e.g. amitriptyline [Elavil], venlafaxine [Effexor]) for
the treatment of your headaches?
a. How many days during the previous month did you use antidepressants for the treatment
of your headaches?
b. How long have you used antidepressants at this frequency?
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7. Are you currently taking antiepileptic drugs (e.g. divalproex sodium [Depakote], sodium
valproate [valproate], topiramate [Topamax]) for the treatment of your headaches?
a. How many days during the previous month did you use antiepileptic drugs for the
treatment of your headaches?
b. How long have you used antiepileptic drugs at this frequency?
8. Are you currently taking beta-blockers (e.g. metoprolol [Lopressor], propranolol [Inderal],
timolol [Timoptic]) for the treatment of your headaches?
a. How many days during the previous month did you use beta-blockers for the treatment of
your headaches?
b. How long have you used beta-blockers at this frequency?
9. Have you received onabotulinumtoxinA [Botox] within the past 6 months for the treatment of
your headaches?
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PATIENT HEALTH QUESTIONNAIRE-9
(PHQ-9)
Over the last 2 weeks, how often have you been bothered by
Not at all

Several
days

More
than half
the days

Nearly
every
day

1. Little interest or pleasure in doing things

0

1

2

3

2. Feeling down, depressed, or hopeless

0

1

2

3

3. Trouble falling or staying asleep, or sleeping too much

0

1

2

3

4. Feeling tired or having little energy

0

1

2

3

5. Poor appetite or overeating

0

1

2

3

6. Feeling bad about yourself — or that you are a failure or have let
yourself or your family down

0

1

2

3

7. Trouble concentrating on things, such as reading the newspaper or
watching television

0

1

2

3

8. Moving or speaking so slowly that other people could have
noticed? Or the opposite — being so fidgety or restless that you
have been moving around a lot more than usual

0

1

2

3

9. Thoughts that you would be better off dead or of hurting yourself
in some way

0

1

2

3

any of the following problems? (Use “✔” to indicate your
answer)

FOR OFFICE CODING 0
=Total Score: ______

+ ______ + ______ + ______

If you checked off any problems, how difficult have these problems made it for you to do your work, take care
of things at home, or get along with other people?
Not difficult at
Somewhat difficult
Very difficult
Extremely
all
difficult
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GAD-7 ANXIETY

Over the last 2 weeks, how often have you
been bothered by the following problems?

Not

More than
Nearly
half the
every day
days

at all

Several
days

1. Feeling nervous, anxious or on edge

0

1

2

3

2. Not being able to stop or control worrying

0

1

2

3

3. Worrying too much about different things

0

1

2

3

4. Trouble relaxing

0

1

2

3

5. Being so restless that it is hard to sit still

0

1

2

3

6. Becoming easily annoyed or irritable

0

1

2

3

7. Feeling afraid as if something awful
might happen

0

1

2

3

(Use “✔” to indicate your answer”

Column totals:

___

+

___

+ ___

+

___

= Total Score _____
If you checked off any problems, how difficult have these problems made it for you to do your
work, take care of things at home, or get along with other people?
Not difficult
at all

Somewhat
difficult

Very
difficult

Extremely
difficult

From the Primary Care Evaluation of Mental Disorders Patient Health Questionnaire (PRIME-MD PHQ). The PHQ was
developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues. For research information, contact Dr.
Spitzer at rls8@columbia.edu. PRIME-MD® is a trademark of Pfizer Inc. Copyright© 1999 Pfizer Inc. All rights reserved.
Reproduced with permission
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PASS – 20
Individuals who experience pain develop different ways to respond to that pain. We would like
to know what you do and what you think about when in pain. Please use the rating scale below
to indicate how often you engage in each of the following thoughts or activities.
Circle one number from 0 (NEVER) to 5 (ALWAYS) for each item.
NEVER
ALWAYS
1. I think that if my pain gets too severe, it will never decrease.

0

1

2

3

4

5

2. When I feel pain, I am afraid that something terrible will
happen.

0

1

2

3

4

5

3. I go immediately to bed when I feel severe pain.

0

1

2

3

4

5

4. I begin trembling when engaged in activity that increases
pain.

0

1

2

3

4

5

5. I can’t think straight when I am in pain.

0

1

2

3

4

5

6. I will stop any activity as soon as I sense pain coming on.

0

1

2

3

4

5

7. Pain seems to cause my heart to pound or race.

0

1

2

3

4

5

8. As soon as pain comes on, I take medication to reduce it.

0

1

2

3

4

5

9. When I feel pain, I think that I may be seriously ill.

0

1

2

3

4

5

10. During painful episodes, it is difficult for me to think of
anything else besides the pain.

0

1

2

3

4

5

11. I avoid important activities when I hurt.

0

1

2

3

4

5

12. When I sense pain I feel dizzy or faint.

0

1

2

3

4

5

13. Pain sensations are terrifying.

0

1

2

3

4

5

14. When I hurt I think about the pain constantly.
15. Pain makes me nauseous (feel sick to my stomach).

0
0

1
1

2
2

3
3

4
4

5
5

16. When pain comes on strong I think I might become
paralyzed or more disabled.

0

1

2

3

4

5

17. I find it hard to concentrate when I hurt.

0

1

2

3

4

5

18. I find it difficult to calm my body down after periods of
pain.
19. I worry when I am in pain.
20. I try to avoid activities that cause pain.

0

1

2

3

4

5

0
0

1
1

2
2

3
3

4
4

5
5

Thank you for completing this questionnaire.
It will help us to better understand your pain problem.
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MEDICATION USE/MISUSE QUESTIONNAIRE
As you answer the following questions pertaining to medication use, medication misuse, and
substance use, please keep in mind that all of your data will remain entirely confidential.
1.) Do you currently have a prescription for a stimulants (e.g. Ritalin, Adderall, Dexedrine)?
a. On average, how frequently have you used stimulants (e.g. Ritalin, Adderall,
Dexedrine) prescribed to you during the past 12 months?
1. Not in the past year
2. Less than once a month
3. Once a month
4. Once a week
5. Multiple times a week
6. Daily
2.) Do you currently have a prescription for opioids NOT for the treatment of headache (e.g.
Vicodin, Oxycotin, Percocet)
a. On average, how frequently have you used opioids (e.g. Vicodin, Oxycotin,
Percocet) prescribed to you during the past 12 months? (Do NOT count opioids
used for headache)
1. Not in the past year
2. Less than once a month
3. Once a month
4. Once a week
5. Multiple times a week
6. Daily
3.) Do you currently have a prescription for anxiolytics (e.g. Xanax, Valium, Klonopin)
a. On average, how frequently have you used anxiolytics (e.g. Xanax, Valium,
Klonopin) prescribed to you during the past 12 months?
1. Not in the past year
2. Less than once a month
3. Once a month
4. Once a week
5. Multiple times a week
6. Daily
4.) Do you currently have a prescription for sedatives (e.g. Ambien, Halcion, Restoril)
a. On average, how frequently have you used sedatives (e.g. Ambien, Halcion,
Restoril) prescribed to you during the past 12 months?
1. Not in the past year
2. Less than once a month
3. Once a month
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4. Once a week
5. Multiple times a week
6. Daily
5.) Have you used stimulants (e.g. Ritalin, Adderall, Dexedrine) WITHOUT a physician’s
prescription during the past 12 months?
a. On average, how frequently have you used stimulants (e.g. Ritalin, Adderall,
Dexedrine) WITHOUT a physician’s prescription during past 12 months?
1. Not in the past year
2. Less than once a month
3. Once a month
4. Once a week
5. Multiple times a week
6. Daily
6.) Have you used opioids not for the treatment of headache (e.g. Vicodin, Oxycotin, Percocet)
WITHOUT a physician’s prescription during the past 12 months?
a. On average, how frequently have you used opioids not for the treatment of
headache (e.g. Vicodin, Oxycotin, Percocet) WITHOUT a physician’s
prescription during past 12 months?
1. Not in the past year
2. Less than once a month
3. Once a month
4. Once a week
5. Multiple times a week
6. Daily
7.) Have you used anxiolytics (e.g. Xanax, Valium, Klonopin) WITHOUT a physician’s
prescription during the past 12 months?
a. On average, how frequently have you used anxiolytics (e.g. Xanax, Valium,
Klonopin) WITHOUT a physician’s prescription during past 12 months?
1. Not in the past year
2. Less than once a month
3. Once a month
4. Once a week
5. Multiple times a week
6. Daily
8.) Have you used sedatives (e.g. Ambien, Halcion, Restoril) WITHOUT a physician’s
prescription during the past 12 months?
a. On average, how frequently have you used sedatives (e.g. Ambien, Halcion,
Restoril) WITHOUT a physician’s prescriptions during past 12 months?
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1.
2.
3.
4.
5.
6.

Not in the past year
Less than once a month
Once a month
Once a week
Multiple times a week
Daily
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SUBSTANCE USE/ABUSE QUESTIONNAIRE
1.) Have you used alcohol during the past 12 months?
a. On average, how frequently have you consumed alcohol during past 12
months?
1. Not in the past year
2. Less than once a month
3. Once a month
4. Once a week
5. Multiple times a week
6. Daily
2.) Have you used tobacco during the past 12 months?
a. On average, how frequently have you used tobacco during past 12 months?
1. Not in the past year
2. Less than once a month
3. Once a month
4. Once a week
5. Multiple times a week
6. Daily
3.) Have you consumed caffeine during the past 12 months?
a. On average, how frequently have you consumed caffeine during past 12
months?
1. Not in the past year
2. Less than once a month
3. Once a month
4. Once a week
5. Multiple times a week
6. Daily
4.) Have you used marijuana/cannabis during the past 12 months?
a. On average, how frequently have you used marijuana/cannabis during past 12
months?
1. Not in the past year
2. Less than once a month
3. Once a month
4. Once a week
5. Multiple times a week
6. Daily
5.) Please indicate whether you have used any of the following substances during your
lifetime:
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a.
b.
c.
d.
e.
f.
g.

“Powder” cocaine
“Crack” cocaine
Methamphetamines (Meth)
Ecstasy (other “club” drugs)
Heroin
Inhalants (cleansers, paint, etc.)
Hallucinogens

6.) Have you found yourself unable to stop using any of the aforementioned drugs when
you wanted to?
7.) Have you ever experienced withdrawal symptoms (felt sick) when you stopped taking
any of the aforementioned drugs?
8.) Have you ever been diagnosed with a substance use disorder (e.g. alcohol abuse, drug
abuse, alcohol dependence, or drug dependence) or treated substance use?
9.) Has anyone in your immediate family ever been diagnosed with a substance use
disorder (e.g. alcohol abuse, drug abuse, alcohol dependence, or drug dependence) or
treated for substance use.
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Publications in Peer-Reviewed Journals
Peck, K. R., Ehrentraut, J. H., & Anghelescu, D. L. (2016). Risk factors for opioid misuse in
adolescents and young adults with focus on oncology setting. Journal of Opioid
Management, 12, 205-216. doi: 10.5055/jom.2016.0333.
Klosky, J. L., Favaro, B., Peck, K. R., Simmons, J. L., Russell, K. M., Green, D. M., & Hudson,
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among young women surviving childhood cancer. Journal of Cancer Survivorship, 10,
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Peck, K. R., Tyc, V. L., Huang, Q., & Zhang, H. (2015). Reduction of secondhand smoke
exposure in the cars of children with cancer. Journal of Pediatric Oncology Nursing, 32,
401-409. doi:10.1177/1043454214563755
Peck, K. R., & Smitherman, T. A. (2015). Mediator variables in headache research:
Methodological critique and exemplar using self-efficacy as a mediator of the
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relationship between headache severity and disability. Headache, 55, 1102-1111. doi:
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Klosky, J. L., Russell, K. M., Simmons, J. L., Foster, R. H., Peck, K. R., Green, D. M., &
Hudson, M. M. (2015). Medical and sociodemographic factors associated with human
papillomavirus (HPV) vaccination adherence among female survivors of childhood
cancer. Pediatric Blood and Cancer, 62, 1630-1636. doi: 10.1002/pbc.25539
Peck, K. R., Smitherman, T. A., & Baskin, S. M. (2015). Traditional and alternative treatments
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McDermott, M. J., Peck, K. R., Walters, A. B., & Smitherman, T. A. (2013). Do
migraineurs selectively attend to headache-related visual stimuli? Headache, 53, 356364. doi: 10.1111/head.12011
Under Review
Peck, K. R., Ehrentraut, J. H., Anghelescu, D. L. (2017). Family and Peer-Group Substance
Abuse as a Risk-Factor Opioid Misuse Behaviors for a Young Adult with Cancer-Related
Pain – A Case Study. Manuscript Submitted for Publication.
Peck, K. R., & Coffey S. F. (2017). Treatment-Seeking Adults with Comorbid Posttraumatic
Stress Disorder, Alcohol Use Disorder, and Opioid Use Disorder: The Effectiveness of
Modified Prolonged Exposure. Manuscript Submitted for Publication.
Hollingsworth, D. W., Gauthier, J., McGuire, A. P., Peck, K. R., Hahn, K., & Conolly, K.
(2017). Intolerance of Uncertainty Mediates Symptoms of PTSD and Depression in
African American Veterans. Manuscript in Preparation.
In Preparation
Peck, K. R., Coffey, S. F., & Connolly, K. M. (2017). Cognitive Processing Therapy for
Veterans Diagnosed with Co-occurring Posttraumatic Stress Disorder and Substance Use
Disorder: The Relationship between Trauma-Related Cognitions and Outcomes of a 6week Treatment Program. Manuscript in Preparation.
DeNadai, A. S., Peck, K. R., Stone, A., Bernecker, S. L., Lynch, R., & Konkle-Parker, D.
(2017). Psychosocial profiles of women with HIV. Manuscript in Preparation.
Book Chapters
Peck, K. R., Johnson, Y. L., & Smitherman, T. A. (2016). Migraine. In C. Rosano, A.
Ikram, & M. Ganguli (Eds.), Neuroepidemiology (Handbook of Clinical Neurology 3rd
series; Vol 138 pp. 2083-294). New York: Elsevier
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Peck, K.R. (2017, June) Pain-Related Anxiety and the Use of Acute Pain Medications in
Relation to Headache Frequency among Individuals Seeking Treatment for Headache.
Presented at the annual convention of the American Headache Society, Boston, MA.
Peck, K. R. (2017, February) Factors Associated with Medication-Overuse Headache in
Patients Seeking Treatment for Primary Headache. Presented at the Annual University
of Mississippi Graduate Student Council Research Symposium, University, MS.
Peck, K. R. (2016, October) Medication Overuse Headache. Presented at the University of
Mississippi Three Minute Thesis Competition, University, MS.
Black, A. K., Peck, K. R., Hamer, J. D., Smitherman, T. A. (2016, April). Relations among fear
of pain, psychological flexibility, and headache-related disability. Presented at the
University of Mississippi Conference on Psychological Science, University, MS.
Zhao, M. S., Peck, K. R., Tynes, B. L., Scott, S., & Maack, D. J. (2016, April). Putting the E in
Ew! Emotion dysregulation mediates the relation between disgust sensitivity and
contamination fear. Presented at the University of Mississippi Conference on
Psychological Science, University of Mississippi, University, MS.
Peck, K. R. & Davis, R. E. (2015, April). Differential effects of psychiatric comorbidities: Are
female and treatment-seeking migraineurs more disabled by their pain? Paper presented
at the University of Mississippi Conference on Psychological Science, University of
Mississippi, University, MS.
Peck, K. R., Ehrentraut, J. H., & Anghelescu, D. L. (2014, July). Aberrant opioidassociated behavior among adolescents and young adult hematology and oncology
patients. Paper presented at Psychology Rounds, St. Jude Children’s Research Hospital,
Memphis, TN.
Peck, K. R. (2013, July). Parent-reported secondhand smoke exposure in the car: Trends and
predictors. Paper presented at Psychology Rounds, St. Jude Children’s Research
Hospital, Memphis, TN.
Poster Presentations
Peck, K. R., Zhao, M. S., & Smitherman, T. A. (2015, June). Gender and its interaction with
depressive symptoms as predictors of disability in chronic migraine. Poster presented at
the annual convention of the American Headache Society, Washington, DC.
Peck, K. R., Nicholson, J., & Tyc, V. L. (2013, November). Mediation and moderation of
secondhand smoke exposure (SHSe): The role of self-efficacy (SE) and perceived
vulnerability in parents of pediatric cancer patients. Poster presented at the annual
convention of the Association of Behavioral and Cognitive Therapies, Nashville, TN.
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Peck, K. R., Moynahan, V. L., & Smitherman, T. A. (2013, November). Relationships between
self-efficacy, headache diagnosis, and impairment. Poster presented at the annual
convention of the Association of Behavioral and Cognitive Therapies, Nashville, TN.
Ehrentraut, J. H., Jurbergs, N., Peck, K. R., Canavera, K., & Willard, T. (2013, October).
Treatment acceptability of a brief, single-session workshop for families of children with
chronic pain. Poster presented at the International Forum on Pediatric Pain, Nova Scotia,
Canada.
Davis, R. E., Peck, K. R., Hamer, J. D., & Smitherman, T. A. (2013, June). Relations between
alcohol use and migraine among young adults. Poster presented at the annual
convention of the American Headache Society, Boston, MA.
Peck, K. R., Nicholson, J., & Tyc, V. L. (2013, April). Parent-reported exposure to secondhand smoke in motor vehicles for children on treatment for cancer. Poster presented at
the National Conference in Pediatric Psychology, New Orleans, LA.
Peck, K. R. (2012, August). Center for Epidemiologic Studies Depression Scale (CES-D) and
Middle-Eastern populations. Poster presented at the annual convention of the Mississippi
Psychological Association, Gulfport, MS.
Peck, K. R., Buscemi, J., Murphy, J. G., (2010, April). Exploration of relations between type of
residence and alcohol consumption in University of Memphis students. Poster presented
at the annual University of Memphis Student Research Forum, Memphis, TN.
Peck, K. R., Buscemi, J., Murphy, J. G., Martens, M. P. McDevitt-Murphy, M. E., Pederson, A.
A., Skidmore, J. R. (2009, November). Characteristics of college students who seek help
for alcohol problems. Poster presented at the annual convention of the Tennessee
Psychology Association, Nashville, TN.
Buscemi, J., Murphy, J. G., Martens, M. P., McDevitt-Murphy, M. E., Pederson, A. A.,
Skidmore, J. R., & Peck, K. R. (2009, November). Help-seeking for alcohol use in
college students: Correlates and preferred methods. Poster presented at the annual
convention of the Association of Behavioral and Cognitive Therapies, Addictive
Behaviors SIG, New York, NY.
GRANT FUNDING
Funded Grants:
Principal Investigator. Factors Associated with Medication Overused Headache in Patients
Seeking Treatment for Primary Headaches. University of Mississippi Graduate Student
Council Research Grant. (4/27/2016-Present). $1000.
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Pediatric Blood and Cancer
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Role: Graduate Research Assistant

2013-2014

Reduction of ETS Exposure in Pediatric Cancer Patients
Principal Investigator: Vida L. Tyc, Ph.D.
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2012-2013

NIH/NCI RO1 CA085406
Department of Psychology, St. Jude Children’s Research Hospital
Role: Graduate Research Assistant
Migraine and Behavioral Health Laboratory
Supervisor: Todd Smitherman, Ph.D.
Department of Psychology, University of Mississippi
Role: Graduate Research Assistant
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Setting: The University of Mississippi Medical Center/VA Medical Center Consortium,
Jackson, MS
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Pre-doctoral Psychology Intern
Spring 2017
Setting: The University of Mississippi Medical Center/VA Medical Center Consortium,
Jackson, MS
Rotations: Community-Based Dual Disorders – Prolonged Exposure
Supervisors: Daniel Williams, Ph.D.
Focus: Prolonged Exposure for PTSD, Behavioral Activation for Depression, and
Dialectical Behavior Therapy
Pre-doctoral Psychology Intern
Winter 2017
Setting: The University of Mississippi Medical Center/VA Medical Center Consortium,
Jackson, MS
Rotations: Community-Based Dual Disorders - Motivational Interviewing
Supervisors: Daniel Williams Ph.D., & Scott Coffey, Ph.D.
Focus: Motivational Interviewing, Prolonged Exposure for PTSD, Behavioral Activation
for Depression, and Dialectical Behavior Therapy
Pre-doctoral Psychology Intern
Fall 2016
Setting: The University of Mississippi Medical Center/VA Medical Center Consortium,
Jackson, MS
Rotations: Evidence Based Practice – Behavioral Medicine
Supervisors: Jeanne Gabriele, Ph.D., Kristi Crane, Psy.D., & Lauren Graves, Ph.D.
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Jackson, MS
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2014-2015
Setting: Haven House, Communicare, Oxford, MS
Supervisors: Scott Gustafson, Ph.D., & John Young, Ph.D.
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